Pub Med ID,Answers,MoA
30738380,"The drug(s) mentioned in the article are cariprazine and risperidone, but the article does not provide information about the mechanism of action, target of the chemical reaction, or receptor subtype(s) being evaluated with. The article focuses on the evaluation of the efficacy of cariprazine in treating negative symptoms of schizophrenia through post hoc analyses of PANSS individual items and PANSS-derived factors.",Partial Agonist
31264510,The receptor(s) are: dopamine. The subtype(s) are: D1 and D5. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D1 and D5 receptor partial agonist.,Partial Agonist
25822479,"The drugs being evaluated in this study are antipsychotics with 5-HT1A receptor partial agonism, specifically perospirone and aripiprazole. The receptor being targeted is the 5-HT1A receptor.",Partial Agonist
26016467,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode(s) for the antipsychotics are: perospirone (full antagonist) and aripiprazole (partial agonist) of D2-R.,Partial Agonist
17628435,The target receptor is: serotonin 5-HT1A. The binding mode is: partial agonist. Therefore the mechanism of action is: serotonin 5-HT1A partial agonist.,Partial Agonist
27371157,The receptor(s) are: nicotinic acetylcholine. The subtype(s) are: α7. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: α7 nicotinic acetylcholine receptor partial agonist.,Partial Agonist
9442338,The receptor(s) are: dopamine. The subtype(s) are: N/A (not specified in the article). The binding mode is: partial agonist. Therefore the mechanism of action is: partial dopamine agonist.,Partial Agonist
33691517,"The drug is: brexpiprazole. The receptor(s) are: dopamine and serotonin. The subtype(s) are: N/A, but the drug is a partial agonist for both receptors. Therefore the mechanism of action is: dopamine/serotonin receptor partial agonist.",Partial Agonist
8905533,The receptor(s) are: GABA-A. The subtype(s) are: partial benzodiazepine receptor agonist. Therefore the mechanism of action is: GABA-A receptor partial agonist.,Partial Agonist
23968123,None,Partial Agonist
24419307,The receptor(s) are: alpha-7 nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha-7 nicotinic acetylcholine partial agonist.,Partial Agonist
16754836,The receptor(s) are: alpha7 nicotinic acetylcholine receptors. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha7 nicotinic cholinergic partial agonist.,Partial Agonist
20728875,The mechanism of action is: partial agonist at α7 nicotinic acetylcholine receptors. The receptor(s) are: α7 nicotinic acetylcholine receptors.,Partial Agonist
19637398,"The receptor(s) are: serotonin. The subtype(s) are: 5-HT1A. The binding mode is: partial agonist. Therefore the mechanism of action is: serotonin 5-HT1A receptor partial agonist. Additionally, the atypical antipsychotics being used have intrinsic activation of 5-HT1A receptors that may hinder the ability of buspirone to improve cognitive function.",Partial Agonist
20033907,"The drug(s) being evaluated are: haloperidol, risperidone, olanzapine, and aripiprazole. The receptor(s) targeted is/are: dopamine D2 receptor. The binding mode(s) can vary as haloperidol is a dopamine antagonist, while risperidone, olanzapine, and aripiprazole are atypical antipsychotics with varying levels of dopamine D2 receptor partial agonist activity. Therefore, the mechanism of action for aripiprazole is: dopamine D2 receptor partial agonist. The article suggests that the partial agonist activity of aripiprazole may reduce the severity of nicotine dependence in schizophrenic patients.",Partial Agonist
19956085,The receptor(s) are: alpha7-nicotinic acetylcholine receptor. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha7-nicotinic receptor partial agonist.,Partial Agonist
18381905,The mechanism of action is: nicotinic agonist activating alpha(7)-nicotinic receptors. The receptor(s) are: nicotinic cholinergic. The subtype(s) are: alpha(7)-nicotinic receptors. The binding mode is: partial agonist.,Partial Agonist
26900078,"The receptor(s) are: dopamine and serotonin. The subtype(s) for dopamine are: D2 and D5. The binding mode for aripiprazole is: partial agonist. Therefore, the mechanism of action is: dopamine D2 and D5 receptor partial agonist, and serotonergic action that results in prefrontal dopamine release. Risperidone is a D2/5-HT2A blocker.",Partial Agonist
23303043,The receptor(s) are: alpha7 nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha7 nicotinic receptor partial agonist.,Partial Agonist
11343682,The receptor(s) are: serotonin. The subtype(s) are: 5-HT(1A). The binding mode is: partial agonist. Therefore the mechanism of action is: serotonin 5-HT(1A) receptor partial agonist.,Partial Agonist
24549101,The receptor(s) are: nicotinic alpha-7. The subtype(s) are: not specified in the article. The binding mode is: partial agonist. Therefore the mechanism of action is: nicotinic alpha-7 receptor partial agonist.,Partial Agonist
26940805,The receptor(s) are: α7 nicotinic acetylcholine receptor. The subtype(s) are: selective agonist. Therefore the mechanism of action is: α7 nicotinic acetylcholine receptor selective agonist.,Partial Agonist
9718289,The receptor(s) are: N-methyl-D-aspartate (NMDA). The subtype(s) are: glycine recognition site. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: NMDA receptor glycine recognition site partial agonist.,Partial Agonist
15474895,"The mechanism of action is: partial agonist at the glycine site of the NMDA-associated receptor complex, noncompetitively enhancing NMDA neurotransmission. The receptor(s) are: NMDA. The subtype(s) are: N/A.",Partial Agonist
1715608,"There are multiple drugs mentioned in this article with different mechanisms of action and receptor subtypes. Some target dopamine D2/D3 receptors, others target serotonin (5HT) receptors or gamma-amino-butyric-acid-A (GABA-A) receptors. The article also mentions drugs that affect multiple receptor subtypes, including D2/D3, 5HT, alpha 1, and/or D1 receptors. Therefore, the mechanisms of action and receptor subtypes vary depending on the specific drug being evaluated.",Partial Agonist
17728426,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 receptor partial agonist.,Partial Agonist
19366489,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode(s) are: partial agonist (for aripiprazole) and full antagonist (for risperidone or olanzapine). Therefore the mechanism of action is: dopamine D2 receptor partial agonist (for aripiprazole) and dopamine D2 receptor antagonist (for risperidone or olanzapine).,Partial Agonist
21068719,The receptor(s) are: GABA. The subtype(s) are: benzodiazepine receptors. The binding mode(s) are: antagonist and partial inverse agonist. Therefore the mechanism of action is: GABA receptor function modulation through benzodiazepine receptor.,Partial Agonist
25438724,The receptor(s) are: α7 nicotinic acetylcholine receptor. The subtype(s) are: α7 subtype. The binding mode is: partial agonist. Therefore the mechanism of action is: selective α7 nicotinic receptor partial agonist.,Partial Agonist
16154544,The receptor(s) are: NMDA-Glycine site. The subtype(s) are: N/A. The binding mode is: endogenous agonist. Therefore the mechanism of action is: NMDA-Glycine site agonist. The drug being evaluated is D-alanine.,Partial Agonist
25363835,The receptor(s) are: nicotinic acetylcholine. The subtype(s) are: alpha7. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha7 nicotinic ACh receptor partial agonist.,Partial Agonist
27613505,The receptor(s) are: nicotinic acetylcholine receptors (nAChR). The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: nicotinic acetylcholine receptor partial agonist.,Partial Agonist
3310672,The mechanism of action and receptor subtype(s) are not specified in the article.,Partial Agonist
25953357,"The receptor(s) are: GABA (gamma-aminobutyric acid) and benzodiazepine. The subtype(s) are: N/A. The binding mode(s) are: antagonist and partial inverse agonist (for benzodiazepine receptor). Therefore, the mechanism of action is: pharmacologically induced GABA deficit and benzodiazepine receptor antagonist/partial inverse agonist, leading to increased vulnerability to the psychotomimetic effects of amphetamine.",Partial Agonist
21145041,The mechanism of action is: γ-aminobutyric acid (GABA)(A) α2/α3 partial agonist. The receptor subtype(s) are: GABA(A) α2/α3 receptors.,Partial Agonist
24114425,The mechanism of action is: nicotinic acetylcholine receptors (nAChRs). The subtype(s) are: N/A for mecamylamine (an nAChR antagonist) and partial agonist for varenicline.,Partial Agonist
23342824,The receptor(s) are: dopamine. The subtype(s) are: D2 and D3. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 and D3 receptor partial agonist.,Partial Agonist
28252452,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 receptor partial agonist.,Partial Agonist
32349117,The receptor(s) are: alpha-7 nicotinic acetylcholine receptors (nAChR). The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha-7 nAChR partial agonist.,Partial Agonist
22952075,The receptor(s) are: alpha7 nicotinic acetylcholine receptor. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha7 nicotinic acetylcholine receptor partial agonist.,Partial Agonist
26834462,The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D3-preferring D3/D2 receptor partial agonist.,Partial Agonist
16300872,"The receptor(s) are: dopamine and 5-HT (serotonin). The subtype(s) are: D2, 5-HT2A, and partial 5-HT1A agonist. The binding mode is: antagonist and partial agonist. Therefore the mechanism of action is: dopamine D2 and serotonin 5-HT2A antagonist, and partial 5-HT1A agonist.",Partial Agonist
27565651,The receptor(s) are: alpha7-nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: alpha7-nicotinic receptor partial agonist.,Partial Agonist
28838583,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: dopamine D2 receptor partial agonist.,Partial Agonist
28478771,The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D3 and D2 receptor partial agonist.,Partial Agonist
27543252,The receptor(s) are: nicotinic acetylcholine. The subtype(s) are: α4β2 and α7. The binding mode(s) are: partial and full agonist. Therefore the mechanism of action is: nicotinic α4β2 and α7 receptor partial and full agonist.,Partial Agonist
25981348,"The receptor(s) are: dopamine. The subtype(s) are: N/A (Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, among others). The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine partial agonist.",Partial Agonist
27427558,The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D3 and D2 receptor partial agonist.,Partial Agonist
33138708,"The drugs being evaluated are varenicline, bupropion, and nicotine replacement therapy (NRT), which are all smoking cessation aids. There is no specific mention of receptor subtypes or mechanisms of action in the article.",Partial Agonist
24096218,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode(s) are: partial agonist for aripiprazole and D2 antagonist for risperidone. Therefore the mechanism of action for aripiprazole is dopamine D2 receptor partial agonist and for risperidone is dopamine D2 receptor antagonist.,Partial Agonist
19238124,"The receptor(s) are: dopamine and serotonin. The subtype(s) for dopamine is: D2, and for serotonin are: 5-HT1A and 5-HT2A. The binding mode is: partial agonist for dopamine D2 receptor, and antagonist for serotonin 5-HT2A receptor. Therefore the mechanism of action is: dopamine D2 receptor partial agonist and serotonin receptor modulator.",Partial Agonist
16810506,The receptor(s) are: dopamine. The subtype(s) are: D2 and D3. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 and D3 receptor partial agonist.,Partial Agonist
21723096,"The drug is D-cycloserine, which is a partial agonist at the glycine site of the NMDA receptor. The receptor subtype(s) is NMDA. Therefore, the mechanism of action is NMDA receptor partial agonist.",Partial Agonist
18765484,"The receptor(s) are: dopamine. The subtype(s) are: N/A, but the drug is described as a dopamine partial agonist. Therefore the mechanism of action is dopamine partial agonist.",Partial Agonist
21432752,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: dopamine partial agonist.,Partial Agonist
19512978,"The receptor(s) are: dopamine and serotonin. The subtype(s) are: D2, 5-HT1A, and 5-HT2A. The binding mode(s) are: high-affinity partial agonist and potent antagonist. Therefore the mechanism of action is: dopamine D2 and serotonin 5-HT1A receptor partial agonist and 5-HT2A receptor antagonist.",Partial Agonist
24412468,The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D3 and D2 receptor partial agonist.,Partial Agonist
20817153,The receptor(s) are: N-methyl-D-aspartate (NMDA). The subtype(s) are: not specified. The binding mode is: partial agonist. Therefore the mechanism of action is: NMDA receptor partial agonist.,Partial Agonist
1679338,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine partial agonist.,Partial Agonist
16237386,The receptor(s) are: serotonin. The subtype(s) are: 5-HT1A. The binding mode is: partial agonist. Therefore the mechanism of action is: serotonin-1A receptor partial agonist.,Partial Agonist
20562170,"The drug being evaluated is buspirone, and the receptor subtype is serotonin-1A (5-HT(1A)). The binding mode is partial agonist. Therefore the mechanism of action is 5-HT(1A) receptor partial agonist. Estrogen is not a drug being evaluated, but rather a physiological hormone being studied for its effect on the interaction with the 5-HT(1A) receptor function.",Partial Agonist
10553752,The receptor(s) are: N-methyl-D-aspartate (NMDA). The subtype(s) are: glycine site on the NMDA receptor. The binding mode is: full agonist. Therefore the mechanism of action is: NMDA receptor glycine full agonist.,Partial Agonist
19387614,"The drug being evaluated is aripiprazole. The receptor(s) targeted are: dopamine D2 and D3, serotonin 1A and 2A (HTR2A). The binding mode(s) are: partial agonist for dopamine receptors and antagonist for serotonin 2A. Therefore, the mechanism of action is: dopamine D2 and D3 partial agonist and serotonin 1A partial agonist/serotonin 2A antagonist.",Partial Agonist
25056368,The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D3 and D2 receptor partial agonist.,Partial Agonist
26730716,The receptor(s) are: nicotinic. The subtype(s) are: N/A. The binding mode is: partial agonist. Therefore the mechanism of action is: nicotinic partial agonist.,Partial Agonist
27807604,The receptor(s) are: dopamine. The subtype(s) are: D2 and D3. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 and D3 receptor partial agonist.,Partial Agonist
21062637,"The receptor(s) are: CB1/2 and NMDA glutamate. The subtype(s) are: N/A for CB1/2, and NMDA for NMDA glutamate. The binding mode(s) are: weak partial agonist or antagonist for CB1/2 and antagonist for NMDA glutamate. Therefore the mechanism of action is: CB1/2 receptor partial agonist or antagonist and NMDA glutamate receptor antagonist.",Partial Agonist
22048460,The receptor(s) are: nicotine acetylcholine. The subtype(s) are: α4β2 and α7. The binding mode(s) are: partial agonist at α4β2 and full agonist at α7. Therefore the mechanism of action is: nicotine acetylcholine receptor partial agonist at α4β2 and full agonist at α7.,Partial Agonist
24923986,"The drug being evaluated is yokukansan (YKS), which is a D2 and 5HT1A partial agonist and 5HT2A and glutamate antagonist. The receptor(s) targeted are dopamine and serotonin, with the subtypes being D2, 5HT1A, and 5HT2A. Therefore, the mechanism of action is: dopamine D2 and serotonin 5HT1A partial agonist and serotonin 5HT2A and glutamate antagonist.",Partial Agonist
32297486,"The drug being evaluated is brexpiprazole, an antipsychotic agent. The mechanism of action and receptor subtype(s) are not specified in the article.",Partial Agonist
21810630,"The drug being evaluated is varenicline, which is a relatively specific α4β2 partial agonist and antagonist, targeting nicotinic acetylcholine receptors (nAChRs). The mechanism of action is to exert α4β2-specific effects while minimizing adverse effects. The specific nAChR subtype being targeted is α4β2.",Partial Agonist
30695290,"The receptor(s) are: dopamine and serotonin. The subtype(s) are: D₃, D₂, and 5-HT1A. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: dopamine D₃/D₂ receptor and serotonin 5-HT1A receptor partial agonist.",Partial Agonist
21616975,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 receptor partial agonist.,Partial Agonist
18848860,"The drug being evaluated is aripiprazole, which is a dopamine partial agonist with high affinity for dopamine D2 receptors. Therefore, the mechanism of action is dopamine D2 receptor partial agonist. There is no mention of any other drug or receptor subtype being evaluated in the article.",Partial Agonist
35012696,"The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. However, the article does not specify the binding mode. Therefore, the mechanism of action is: dopamine D3 and D2 receptor agonist or partial agonist (depending on the binding mode).",Partial Agonist
26075487,The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D3 and D2 receptor partial agonist.,Partial Agonist
19302829,The receptor(s) are: dopamine. The subtype(s) are: D2 and D3. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 and D3 receptor partial agonist.,Partial Agonist
21105281,"The receptor(s) are: serotonin. The subtype(s) are: 5-HT1A. The binding mode is: partial agonist. Therefore the mechanism of action is: serotonin 5-HT1A receptor partial agonist. Additionally, the drugs being evaluated are: risperidone (antipsychotic agent) and buspirone (serotonin 5-HT1A receptor agonist).",Partial Agonist
16723179,"The receptor(s) are: dopamine D2 and 5-HT2A, and partial agonist for 5-HT1A. The binding mode(s) are: antagonist for D2 and 5-HT2A, and partial agonist for 5-HT1A. Therefore the mechanism of action is: dopamine D2/5-HT2A antagonist and partial 5-HT1A agonist.",Partial Agonist
22198450,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 receptor partial agonist.,Partial Agonist
16140281,"The receptor(s) are: gamma-aminobutyric acid type A (GABA(A)) and serotonergic (5-HT(2A/2C)). The subtype(s) are: N/A for GABA(A) and 5-HT(2A/2C) for serotonergic. The binding mode(s) are: antagonist and partial inverse agonist for GABA(A) and partial agonist for serotonergic. Therefore the mechanism of action is: GABA(A) receptor antagonist and partial inverse agonist, and serotonergic 5-HT(2A/2C) receptor partial agonist.",Partial Agonist
15023571,"The target is the glycine transporter-1, and the drug is N-methylglycine (sarcosine), which is an endogenous antagonist of the transporter. The receptor subtype(s) referenced in the article is the glycine site of the N-methyl-D-aspartate receptor, which is potentiated by glycine's action. The binding mode is not specified, but sarcosine is described as potentiating glycine's action, which suggests it may be acting as an agonist. Therefore, the mechanism of action is glycine transporter-1 inhibition and potential agonist effects on the glycine site of the N-methyl-D-aspartate receptor.",Partial Agonist
19451828,The receptor(s) are: dopamine. The subtype(s) are: D2. The binding mode is: partial agonist. Therefore the mechanism of action is: dopamine D2 receptor partial agonist.,Partial Agonist
7541598,"There are multiple drugs mentioned in the article with different mechanisms of action and receptor subtypes. Levodopa, amphetamines, and bromocriptine are dopamine agonists, and MAR 327 is a partial dopamine agonist. Tricyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors affect serotonin transmission. Glycine and NMDA modulators affect GABAergic transmission. Clozapine and risperidone are combined serotonin/dopamine antagonists, specifically targeting 5-HT2 and D2 receptors.",Partial Agonist
14609439,"The receptor(s) are: dopamine and serotonin. The subtype(s) for dopamine are D2 and 5-HT1A, and for serotonin it is 5-HT2A. The binding mode is: dopamine D2 partial agonist, dopamine 5-HT1A partial agonist, and serotonin 5-HT2A antagonist. Therefore the mechanism of action is: dopamine and serotonin receptor partial agonist and antagonist.",Partial Agonist
1348584,"The receptor(s) are: dopamine. The subtype(s) are: N/A, but terguride is a partial dopamine agonist. Therefore the mechanism of action is: dopamine partial agonist.",Partial Agonist
8102048,"The drug being evaluated is m-chlorophenylpiperazine (MCPP), which is a serotonin partial agonist. The receptor subtype(s) are not specified in the article.",Partial Agonist
19386475,The receptor(s) are: serotonin-5-HT(1A). The subtype(s) are: 5-HT(1A). The binding mode is: partial agonist. Therefore the mechanism of action is: serotonin-5-HT(1A) receptor partial agonist.,Partial Agonist
29619682,The mechanism of action is a multimodal dopamine (D)-serotonin (5-HT) stabilizer with partial agonist activity for D. The subtype(s) of the receptors are not specified in the abstract.,Partial Agonist
12084415,The receptor(s) are: NMDA. The subtype(s) are: glycine recognition site. The binding mode is: partial agonist. Therefore the mechanism of action is: NMDA receptor partial agonist at the glycine recognition site.,Partial Agonist
8944393,The drug being evaluated is meta-chlorophenylpiperazine (mCPP) which is a serotonin (5-HT) receptor partial agonist with high affinity for 5-HT1C binding sites. The receptor subtype(s) being targeted are 5-HT1C binding sites.,Partial Agonist
10071726,The mechanism of action is: partial agonist at the glycine recognition site of the NMDA receptor. The receptor subtype(s) are: NMDA.,Partial Agonist
11720694,The receptor(s) are: serotonin. The subtype(s) are: 5-HT1A. The binding mode is: partial agonist. Therefore the mechanism of action is: serotonin 5-HT1A receptor partial agonist.,Partial Agonist
15061240,"The receptor(s) are: N-methyl-D-aspartate (NMDA) receptors. The subtype(s) are: N/A. The binding mode(s) are: full agonists, specifically glycine and D-serine, and partial agonist, specifically D-cycloserine. Therefore the mechanism of action is: NMDA receptor agonists, with full agonists potentially being more effective than partial agonists in treating persistent negative symptoms of schizophrenia.",Partial Agonist
22697189,The receptor(s) are: dopamine. The subtype(s) are: partial agonist. The binding mode is: intramuscular depot formulation. Therefore the mechanism of action is: dopamine D2 receptor partial agonist.,Partial Agonist
9466160,"The drug(s) being evaluated are buspirone and mianserin. 
The receptor(s) are: serotonin. 
The subtype(s) for buspirone is 5-HT1A (partial agonist) and for mianserin is 5-HT2A/2C (antagonist).
Therefore, the mechanism of action for buspirone is: serotonin 5-HT1A partial agonist, and for mianserin is: serotonin 5-HT2A/2C antagonist.",Partial Agonist
7625475,The receptor(s) are: N-methyl-D-aspartate (NMDA) subtype of glutamate. The subtype(s) are: glycine-site. The binding mode is: partial agonist. Therefore the mechanism of action is: partial agonist at the glycine site of the NMDA subtype of the glutamate receptor.,Partial Agonist
9564205,The receptor(s) are: dopamine autoreceptors and dopamine D2/D3 receptors. The binding mode(s) are: agonist and partial agonist. Therefore the mechanism of action is: dopamine autoreceptor agonist and partial dopamine D2/D3 agonist.,Partial Agonist
15502972,The receptor(s) are: N-methyl-D-aspartate (NMDA). The subtype(s) are: glycine site. The binding mode is: partial agonist. Therefore the mechanism of action is: NMDA receptor partial agonist at the glycine site.,Partial Agonist
32868522,"The drug being evaluated is aripiprazole, which is a dopamine partial agonist. The receptor subtype being targeted is the dopamine D2 receptor.",Partial Agonist
12860772,"The receptor(s) are: dopamine and serotonin. The subtype(s) are: D2, 5HT1A, and 5HT2A. The binding mode(s) are: partial agonist for dopamine D2 and serotonin 5HT1A receptors, and antagonist for serotonin 5HT2A receptors. Therefore, the mechanism of action is: dopamine D2 and serotonin 5HT1A partial agonist and serotonin 5HT2A antagonist.",Partial Agonist
28558941,The drug(s) mentioned in the article are aripiprazole and risperidone. The mechanism of action is partial dopamine D2-receptor agonist for aripiprazole and dopamine receptor antagonist for risperidone. The receptor subtype(s) mentioned are the dopamine D2-receptor for aripiprazole and dopamine receptors in general for risperidone.,Partial Agonist
9892252,The receptor(s) are: N-methyl-D-aspartate (NMDA). The subtype(s) are: glycine modulatory site of NMDA receptor. The binding mode is: partial agonist. Therefore the mechanism of action is: partial agonist at the glycine modulatory site of the NMDA receptor.,Partial Agonist
18597078,The receptor(s) are: dopamine. The subtype(s) are: N/A (the drug has a unique receptor-binding profile). The binding mode is: partial agonist. Therefore the mechanism of action is: partial dopamine agonist with potential antipsychotic properties.,Partial Agonist
28215471,"The mechanism of action is: dopamine serotonin stabilizer. The receptor(s) are: dopamine and serotonin, but specific subtypes are not mentioned. The binding mode is not specified.",Partial Agonist
31688449,"The drug(s) being evaluated in this study are antipsychotics, including haloperidol, flupentixol, olanzapine, and aripiprazole. The target of the chemical reaction is the dopamine D2 receptor, and their binding mode is as antagonists for haloperidol, flupentixol, and olanzapine, and as a partial agonist for aripiprazole.",Partial Agonist
16766110,"The drug(s) being evaluated in this study are olanzapine, selective serotonin reuptake inhibitors (SSRI), and benzodiazepines (BZD). The article does not specify the receptor subtype(s) that these drugs act on.",Partial Agonist
22729212,"There is no drug being evaluated in this study. The study is evaluating the effect of different doses of nicotine transdermal patch on smoking reduction and cessation in hospitalized schizophrenic patients. Nonetheless, the mechanism of action of nicotine is as a nicotinic agonist.",Partial Agonist
23609378,The article does not provide information about the specific drugs being evaluated and their mechanism of action or receptor subtype targeted. It only discusses the classification of antipsychotics into typical and atypical categories and their effects on smoking reduction in schizophrenic patients.,Partial Agonist
7870880,"The drugs being evaluated in this study are SDZ HDC-912 and OPC-4392, both of which have dopaminergic properties. SDZ HDC-912 is a dopamine D2 receptor partial agonist, while OPC-4392 acts as an agonist at presynaptic dopamine autoreceptors and as an antagonist at post-synaptic D2 receptors. The benzamide derivative amisulpride is also included in the study as a comparison. Therefore, the mechanism of action is dopamine receptor modulation, with varying subtype preferences depending on the specific drug.",Partial Agonist
17728427,"The drug being evaluated is aripiprazole. The receptors and binding modes are: dopamine D2 receptor partial agonist, 5-HT2 receptor antagonist, and serotonin 5-HT1A receptor partial agonist.",Partial Agonist
34861170,The receptor(s) are: serotonin 5-HT2A. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: selective serotonin 5-HT2A receptor antagonist.,Partial Agonist
23523692,"The mechanism of action and receptor subtype are not explicitly stated in the article. However, it is mentioned that the drug being tested is MK-0249, which is described as a histamine H3 inverse agonist. Therefore, the target of the chemical reaction is the histamine H3 receptor and the binding mode is inverse agonist.",Partial Agonist
19907417,The receptor(s) are: serotonin 5-HT2A. The subtype(s) are: N/A. The binding mode is: inverse agonist. Therefore the mechanism of action is: serotonin 5-HT2A receptor inverse agonist.,Partial Agonist
36190440,The receptor(s) are: serotonin 5-HT2A. The subtype(s) are: inverse agonist/antagonist. Therefore the mechanism of action is: selective serotonin 5-HT2A receptor inverse agonist/antagonist.,Partial Agonist
22954754,The receptor(s) are: serotonin 5-HT2A and dopamine D2. The subtype(s) are: selective 5-HT2A-inverse agonist. The binding mode is: inverse agonist. Therefore the mechanism of action is: enhancement of 5-HT2A receptor blockade and partial agonist activity at dopamine D2 receptors.,Partial Agonist
34404290,"The article mentions pimavanserin, but it does not provide information about its mechanism of action or its target receptor subtype. The abstract only lists indications that the drug is being evaluated for, including antipsychotic treatment, major depressive disorder, and psychotic disorders.",Partial Agonist
23764683,The receptor(s) are: histamine H2. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: histamine H2 receptor antagonist.,Partial Agonist
24844747,"The drug being evaluated is tiagabine, which inhibits the GAT1 GABA uptake transporter and increases synaptic GABA levels. The receptor subtype being evaluated is the GABA-benzodiazepine receptor (GABA-BZR), with a focus on the α1 and α5 subtypes. Therefore, the mechanism of action is synaptic inhibition via GABA-BZR activation.",Partial Agonist
3977547,"The drugs being evaluated are dopamine agonists, including apomorphine, dopamine hydrochloride, and levodopa-carbidopa. The receptor(s) being targeted is the dopamine receptor subtype(s), but it is not specified which subtype(s) are involved in this study. Therefore, the mechanism of action is dopamine agonist.",Partial Agonist
33626254,The receptor(s) are: muscarinic. The subtype(s) are: N/A. The binding mode(s) are: agonist (for xanomeline) and antagonist (for trospium). Therefore the mechanism of action is: muscarinic cholinergic receptor agonist (for xanomeline) and peripheral antagonist (for trospium) for schizophrenia.,Agonist
32294346,"The receptor(s) are: trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A). The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: agonist activity at TAAR1 and 5-HT1A receptors, and does not act on dopamine D2 receptors.",Agonist
9875725,The receptor(s) are: serotonin and dopamine. The subtype(s) are: 2A and unspecified for dopamine. The binding mode(s) are: agonist for serotonin-2A and unspecified for dopamine. Therefore the mechanism of action is: serotonin-2A agonist action.,Agonist
35191924,"The receptor(s) are: α2A-adrenergic receptors. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore, the mechanism of action is: selective α2A-adrenergic receptor agonist.",Agonist
28601891,The mechanism of action is: glucagon-like peptide-1 receptor agonist. The target of the chemical reaction is the GLP-1 receptor.,Agonist
36198061,The receptor(s) are: adrenergic alpha-2. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: adrenergic alpha-2 receptor agonist. The drug being evaluated is dexmedetomidine.,Agonist
2869745,The receptor(s) are: dopamine. The subtype(s) are: autoreceptor. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine agonist targeting the dopamine autoreceptor.,Agonist
30355445,"The receptor(s) are: serotonin and dopamine. The subtype(s) are: 5-HT2A. The binding mode(s) are: agonist and antagonist. Therefore the mechanism of action is: LSD agonist activity at various serotonin (5-HT) and dopamine receptors, and Ketanserin as a selective 5-HT2A receptor antagonist.",Agonist
32893328,The receptor(s) are: sphingosine-1-phosphate (S1P). The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: S1P receptor agonist.,Agonist
28825423,"The receptor(s) are: alpha7-nicotinic acetylcholine receptor (nAChR). The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore, the mechanism of action is: alpha7-nicotinic receptor agonist.",Agonist
18593778,"The receptor(s) are: acetylcholine muscarinic. The subtype(s) are: M(1) and M(4). The binding mode(s) are: agonist. Therefore, the mechanism of action is: selective muscarinic type 1 and type 4 receptor agonist.",Agonist
34996406,"The mechanism of action is to activate the GLP-1 receptor, and the drug being evaluated is Liraglutide 3mg, which is a GLP-1 receptor agonist. The receptor subtype is GLP-1.",Agonist
21173788,The receptor(s) are: metabotropic glutamate 2/3 (mGlu2/3) and serotonin 2A. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: mGlu2/3 agonist and serotonin 2A agonist.,Agonist
28590364,The mechanism of action is inhibiting glycine transport. The receptor subtype(s) being evaluated are NMDAR (N-methyl-D-aspartate receptor).,Agonist
26071208,The receptor(s) are: alpha-7 nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode(s) are: full agonist. Therefore the mechanism of action is: alpha-7 nicotinic receptor full agonist.,Agonist
36066977,The receptor(s) are: glucagon-like peptide-1 (GLP-1) receptor. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonist.,Agonist
33308348,"The article discusses the use of liraglutide, a glucagon-like peptide-1 receptor agonist, as a treatment for prediabetic, overweight/obese schizophrenia-spectrum disorder patients. The article does not specify any additional drugs being evaluated.",Agonist
35921506,"The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine agonist. Specifically, the drug being evaluated is pramipexole, which is a dopamine agonist.",Agonist
26966119,"The receptor(s) are: dopamine. The subtype(s) are: D1. The binding mode(s) are: full, selective agonist. Therefore, the mechanism of action is: dopamine-1 receptor agonist.",Agonist
28922590,The receptor(s) are: α7-nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: α7-nicotinic acetylcholine receptor agonist.,Agonist
26089183,The receptor(s) are: α7 nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: α7 nicotinic acetylcholine receptor agonist.,Agonist
25028065,"There is no mention of a specific drug in this article, therefore there is no mechanism of action or receptor subtype specified. The article is focused on the reliability, validity, and treatment sensitivity of the Schizophrenia Cognition Rating Scale.",Agonist
1581424,The receptor(s) are: serotonin. The subtype(s) are: 5-HT1C/5-HT2. The binding mode(s) are: agonist. Therefore the mechanism of action is: centrally acting 5-HT1C/5-HT2 agonist.,Agonist
27717222,The receptor(s) are: GLP-1. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonist.,Agonist
25006819,The receptor(s) are: metabotropic glutamate. The subtype(s) are: 2/3. The binding mode(s) are: agonist. Therefore the mechanism of action is: metabotropic glutamate 2/3 receptor agonist.,Agonist
26018529,"There are no drugs being evaluated in this article, as it is a study comparing two cognitive assessment batteries in schizophrenia.",Agonist
18548234,The mechanism of action is: nicotinic agonist. The receptor subtype(s) are: nicotinic acetylcholine receptors.,Agonist
20571979,The receptor(s) are: metabotropic glutamate. The subtype(s) are: mGluR2/3. The binding mode(s) are: agonist. Therefore the mechanism of action is: mGluR2/3 agonist.,Agonist
22750632,The receptor(s) are: α2-adrenoceptor. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: α2-adrenoceptor agonist.,Agonist
27319970,The receptor being evaluated is the α7 nicotinic receptor. The mechanism of action is an agonist. The drug is ABT-126.,Agonist
21220791,"The mechanism of action is: dopamine agonist antidepressant.
The receptor(s) and subtype(s) are: dopamine but it is not specified which subtype.",Agonist
17467956,The receptor(s) are: dopamine. The subtype(s) are: D1. The binding mode(s) are: full agonist. Therefore the mechanism of action is: dopamine D1 receptor full agonist.,Agonist
35277995,"The mechanism of action is: agonist of GPR139. The receptor subtype is: orphan G-protein-coupled receptor, GPR139.",Agonist
22926591,The receptor(s) are: sigma-1. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: sigma-1 receptor agonist with the drug fluvoxamine.,Agonist
17596915,The receptor(s) are: dopamine. The subtype(s) are: D1. The binding mode(s) are: full agonist. Therefore the mechanism of action is: full D1 dopamine agonist.,Agonist
33879769,"The receptor(s) are: TAAR1 and 5-HT1A. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore, the mechanism of action is: TAAR1/5-HT1A agonist.",Agonist
30633660,"The drug being evaluated is glycine. The article does not mention any specific receptors or mechanism of action for glycine. Glycine is an amino acid and has been studied for its NMDA receptor modulating properties in relation to schizophrenia, but this information is not provided in this particular abstract.",Agonist
29338621,"The receptor(s) are: α7 nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: α7 nicotinic acetylcholine receptor agonist. The drug being evaluated is CDP-choline, which is a supplement with α7 nicotinic acetylcholine receptor agonist properties.",Agonist
16005384,The mechanism of action is: dopamine agonist. The receptor subtype(s) are: N/A.,Agonist
22727707,The receptor(s) are: peroxisome proliferator-activated receptor-γ (PPAR-γ). The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: PPAR-γ agonist.,Agonist
19223439,"The drug being evaluated in this study is secretin, which is a hormonal agonist for the group B G-protein-coupled receptors. The mechanism of action and receptor subtype(s) for the drug have not been specifically stated in this article. However, it is mentioned that secretin acts as a retrograde messenger and neuromodulator on basket and Purkinje cells in the cerebellum, which are important for eye-blink conditioning.",Agonist
119270,"The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine agonist (specifically bromocriptine and CF 25-397, both ergot derivatives).",Agonist
30797222,"The drug being evaluated is clonidine, which is an α2-adrenergic receptor agonist. The target of the chemical reaction is the noradrenergic system. The subtype(s) are α2-adrenergic receptors. The binding mode(s) are agonist. Therefore, the mechanism of action is stimulation of the α2-adrenergic receptors in the noradrenergic system.",Agonist
6372924,The mechanism of action and receptor subtype(s) are not specified in the article.,Agonist
23399382,The article is not evaluating a drug and therefore does not have a mechanism of action or receptor subtype. It is studying the effects of nicotine on cognitive performance in individuals with schizophrenia and healthy controls.,Agonist
28318835,The mechanism of action is N-methyl-d-aspartate-type (NMDAR) glycine-site agonist. The receptor subtype is NMDAR.,Agonist
14720317,"There is no specific drug being evaluated in this article. It is a study comparing plasma levels of glycine and serine in patients with schizophrenia, major depression, and normal controls. The focus is on the role of glycine as a co-agonist at NMDA receptors and its relationship to negative symptoms in schizophrenia.",Agonist
9088887,The receptor(s) are: dopamine. The subtype(s) are: D2/D3 autoreceptor. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine D2/D3 autoreceptor agonist.,Agonist
2404964,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: agonist and antagonist. Therefore the mechanism of action is: dopamine agonist and antagonist.,Agonist
28117049,The mechanism of action and receptor subtype(s) of the drug bitopertin are not specified in the article.,Agonist
29181816,There is no drug being evaluated in this article; the study is investigating the effects of transdermal nicotine on cognitive control in individuals with schizophrenia.,Agonist
9836012,The receptor(s) are: NMDA glutamate. The subtype(s) are: glycine site. The binding mode(s) are: full agonist. Therefore the mechanism of action is: full agonist of the glycine site of NMDA receptor.,Agonist
26518728,There is no drug being evaluated in this study. The study examines the effects of nicotine on neuronal response in patients with schizophrenia during auditory selective attention.,Agonist
36414626,The mechanism of action is muscarinic receptor agonist. The receptor subtype is not specified in the abstract.,Agonist
29699895,There are no drugs being evaluated in this article. The article is investigating the association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia.,Agonist
19713300,"The drug being evaluated in this study is nicotine, which is a nicotinic agonist targeting nicotinic acetylcholine receptors in the brain.",Agonist
36797233,"There are no drugs being evaluated in this article. Rather, the article discusses the functional connectivity signatures of NMDAR dysfunction in schizophrenia and integrates findings from imaging genetics and pharmaco-fMRI.",Agonist
25881753,"The article does not provide information on the mechanism of action or receptor subtype of pomaglumetad methionil, as the focus is on its potential effect on the QT interval in subjects with schizophrenia.",Agonist
19440071,"The receptor(s) are: serotonin receptor 1A and dopamine. The subtype(s) are: 1A, D2 and D3. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: serotonin receptor 1A agonist properties and dopamine D2/D3 receptor partial agonist.",Agonist
1099172,"The receptor(s) are: dopamine. The subtype(s) are: unspecified. The binding mode(s) are: agonist. Therefore, the mechanism of action is: dopamine receptor agonist.",Agonist
24106334,The receptor(s) are: α2-noradrenergic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: α2-noradrenergic agonist. The drug being evaluated is clonidine.,Agonist
36584503,The receptor(s) are: trace amine-associated. The subtype(s) are: TAAR1. The binding mode(s) are: agonist. Therefore the mechanism of action is: TAAR1 agonist.,Agonist
15729086,The receptor(s) are: histamine H1 and H3. The subtype(s) are: N/A. The binding mode(s) are: agonist/antagonist (enhancer with H1 agonistic/H3 antagonistic properties). Therefore the mechanism of action is: histamine H1 receptor agonist/H3 antagonist.,Agonist
17443126,"The mechanism of action is: nicotinic acetylcholine receptor agonist.
The receptor subtype is: neuronal nicotinic acetylcholine receptor (nAChR) system.",Agonist
19887019,"The receptor(s) are: glycine transporter-1 (GlyT-1). The subtype(s) are: N/A. The binding mode(s) are: antagonist. Therefore, the mechanism of action is: GlyT-1 antagonist. The drug being evaluated in this study is sarcosine (N-methylglycine).",Agonist
25539791,The receptor(s) are: metabotropic glutamate mGluR2 and mGluR3. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: selective agonist for the metabotropic glutamate mGluR2 and mGluR3 receptors.,Agonist
27805978,"The receptor(s) are: melatonergic MT1/MT2 and 5-HT2C. The subtype(s) are: N/A. The binding mode(s) are: agonist and antagonist. Therefore, the mechanism of action is: agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist.",Agonist
22425471,There is no drug being evaluated in this article. The article is discussing the effects of nicotine on auditory change detection in schizophrenia patients with auditory verbal hallucinations.,Agonist
28541645,"The receptor(s) are: estrogen. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore, the mechanism of action is: estrogen agonist.",Agonist
33373806,The receptor(s) are: glucagon-like peptide-1 (GLP-1) receptors. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonist.,Agonist
23137805,"The article is not discussing a drug or medication, so there is no mechanism of action or receptor subtype mentioned.",Agonist
18923067,The receptor(s) are: GABA type A (GABA(A)). The subtype(s) are: alpha(2) and alpha(3). The binding mode(s) are: selective agonist. Therefore the mechanism of action is: selective agonist activity at GABA(A) receptors containing alpha(2) or alpha(3) subunits.,Agonist
28260235,The receptor(s) are: glucagon-like peptide-1 (GLP-1). The subtype(s) are: GLP-1 receptors. The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonism.,Agonist
22088556,The receptor(s) are: α4β2 central neuronal nicotinic receptors (NNRs). The subtype(s) are: N/A. The binding mode(s) are: selective agonist. Therefore the mechanism of action is: α4β2 central neuronal nicotinic receptor (NNR) selective agonist.,Agonist
25382826,The drug(s) being evaluated are: pomaglumetad methionil (prodrug) and LY404039 (active moiety/metabotropic glutamate 2/3 receptor agonist). The mechanism of action is: agonist. The receptor subtype(s) targeted are: metabotropic glutamate 2/3 receptor.,Agonist
12472985,The mechanism of action is potassium channel opener/activator. There is no mention of any specific receptor subtype(s) being evaluated. The drug being evaluated is diazoxide.,Agonist
25074637,The receptor(s) are: dopamine. The subtype(s) are: D1. The binding mode(s) are: full agonist. Therefore the mechanism of action is: D1 dopamine receptor full agonist.,Agonist
32450497,"The receptor(s) are: dopamine. The subtype(s) are: not specified, though brexpiprazole is a partial agonist of D2 and 5-HT1A receptors. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine agonist (partial agonist of D2 receptor) and possibly 5-HT1A receptor partial agonist as well, though not directly mentioned in the article.",Agonist
8981389,"The receptor(s) are: serotonin. The subtype(s) are: 5-HT. The binding mode(s) are: agonist. Therefore the mechanism of action is: serotonin receptor agonist. Additionally, methylphenidate is a dopamine uptake inhibitor, meaning its mechanism of action is blocking the reuptake of dopamine, increasing its availability in the brain.",Agonist
19440079,The receptor(s) are: cannabinoid. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: cannabinoid agonist.,Agonist
18096137,The drug(s) being evaluated are: sustained-release bupropion and transdermal nicotine patch. The mechanism of action for sustained-release bupropion is: antidepressant and aid for smoking cessation. The mechanism of action for the transdermal nicotine patch is: nicotine agonist. There is no information provided regarding receptor subtypes or binding modes.,Agonist
20226539,"There are no drugs being evaluated in this article, therefore there are no mechanism of action(s) or receptor subtype(s) to identify.",Agonist
15780844,The receptor(s) are: NMDA glutamate. The subtype(s) are: glycine site. The binding mode(s) are: full agonist. Therefore the mechanism of action is: selective full agonist at the glycine site of N-methyl-D-aspartate glutamate receptor.,Agonist
11579010,The receptor(s) are: serotonin. The subtype(s) are: 5-HT1A. The binding mode(s) are: agonist. Therefore the mechanism of action is: serotonin-1A (5-HT(1A)) agonist.,Agonist
23239133,"The drugs being evaluated are reboxetine and betahistine. The receptor(s) are: norepinephrine and histamine H1/H3. The subtype(s) are: selective norepinephrine reuptake inhibitor and histamine H1 receptor agonist/H3 antagonist. The binding mode(s) are: inhibitor and agonist/antagonist. Therefore, the mechanism of action is: complementary action in CNS pathways regulating appetite and body weight through selective norepinephrine reuptake inhibition and histamine H1 receptor agonism/H3 antagonism.",Agonist
25679135,The receptor(s) are: ionotropic N-methyl-d-aspartate. The subtype(s) are: N/A. The binding mode(s) are: antagonist. Therefore the mechanism of action is: ionotropic N-methyl-d-aspartate receptor antagonist.,Agonist
21508856,"The mechanism of action is the activation of metabotropic glutamate (mGlu) 2/3 receptors, through the prodrug LY2140023 monohydrate, which is converted to the potent mGlu 2/3 receptor agonist LY404039. The receptor subtype(s) targeted are mGlu 2/3. The study also included an active control, olanzapine, which is an antipsychotic agent targeting dopamine and serotonin receptors.",Agonist
11522468,The receptor(s) are: alpha-2a noradrenergic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: alpha-2a noradrenergic agonist. The drug being evaluated is guanfacine.,Agonist
23422399,The receptor(s) are: nicotinic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: nicotinic agonist.,Agonist
24401727,The receptor(s) are: glucagon-like peptide-1 (GLP-1) receptor. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonist.,Agonist
1684439,The receptor(s) are: dopamine. The subtype(s) are: autoreceptors. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine autoreceptor agonist.,Agonist
21346734,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: dopamine partial agonist.,Agonist
34751928,"The drug(s) being evaluated are: TAAR1 agonist Ulotaront. The receptor(s) are: trace amine-associated receptor 1 (TAAR1) and dopamine D2 receptor. The subtype(s) are: N/A. The binding mode(s) are: agonist for TAAR1 and not specified for dopamine D2. Therefore, the mechanism of action is: TAAR1 agonist and potential action on dopamine D2 receptor.",Agonist
20130535,The receptor(s) are: dopamine. The subtype(s) are: D1 and D2. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine agonist targeting D(1) and D(2) receptors.,Agonist
31101513,"The receptor(s) are: serotonin and GABA. The subtype(s) are: not specified for serotonin, and for GABA it is presumed to be the GABAB receptor. The binding mode(s) are: agonist for both serotonin and GABA. Therefore the mechanism of action is: co-treatment with serotonin receptor agonist and GABAB receptor agonist. However, it should be noted that the article only mentions buspirone, which acts as a serotonin receptor agonist, and does not mention a specific GABAB receptor agonist.",Agonist
24022237,The receptor(s) are: nicotinic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is nicotinic receptor agonist.,Agonist
32513424,"The drugs being evaluated are NMDA receptor agonists/antagonists (D-cycloserine/dextromethorphan) and dopamine type 2 receptor agonists/antagonists (bromocriptine/haloperidol). The mechanism of action for NMDA receptor agonists/antagonists is modulation of glutamatergic neurotransmission, and the receptor subtype is NMDA. The mechanism of action for dopamine type 2 receptor agonists/antagonists is modulation of dopamine neurotransmission, and the receptor subtype is D2.",Agonist
7932282,"The drug being evaluated is RS 86, which is a muscarinic agonist. The receptor subtype(s) are muscarinic receptors. Therefore the mechanism of action is: muscarinic agonist.",Agonist
17299516,The receptor(s) are: serotonin. The subtype(s) are: 5-HT2A. The binding mode(s) are: agonist. Therefore the mechanism of action is: serotonin 5-HT2A receptor agonist.,Agonist
23081705,"There are no drugs being evaluated in this article. The study is investigating the effects of nicotine on social cognition, social competence, and self-reported stress in schizophrenia patients and healthy controls.",Agonist
1358231,"The drug being evaluated in this study is muscimol, a GABA agonist. The receptor subtype being targeted is the GABA-A receptor. Therefore, the mechanism of action is GABA-A receptor agonist.",Agonist
24613032,The receptor(s) are: 5-HT2C. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: 5-HT2C receptor agonist.,Agonist
2906947,The receptor(s) are: beta-adrenergic. The subtype(s) are: N/A. The binding mode(s) are: antagonist. Therefore the mechanism of action is: beta-adrenergic antagonists.,Agonist
15138435,"The article is not discussing the evaluation of a drug, but rather the effects of nicotine on cognitive deficits in schizophrenia. However, the article does mention that nicotine activates nicotinic receptors which have a pathophysiological role in schizophrenia.",Agonist
11806864,The mechanism of action is: agonist at brain N-methyl-D-aspartate receptors. The receptor subtype(s) are: NMDA receptors. The drug being evaluated is glycine.,Agonist
8830068,"The receptor(s) are: alpha 2-adrenergic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: alpha 2-adrenergic agonist. The antipsychotic agent being evaluated is haloperidol, and the alpha 2-adrenergic agonist being evaluated is clonidine.",Agonist
15817136,"The article is not specifically evaluating a drug's mechanism of action or receptor subtype(s). However, it does mention that clozapine is an atypical antipsychotic drug with multiple effects on glutamatergic activity.",Agonist
20363089,"There are no drugs mentioned in this article, therefore there is no mechanism of action or receptor subtype being evaluated.",Agonist
24035403,The receptor(s) are: metabotropic glutamate receptor 2/3. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: metabotropic glutamate receptor 2/3 agonist.,Agonist
22697191,The receptor(s) are: nicotinic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: nicotinic agonist.,Agonist
33932162,There are no drugs being evaluated in this study. The study is evaluating the effects of cannabis use and acute nicotine administration on sensory gating in the brain.,Agonist
35438304,"The mechanism of action is: delta-9 tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis. The receptor(s) are: cannabinoid receptors. The subtype(s) are not specified in the article. Therefore the mechanism of action is: cannabinoid receptor agonist.",Agonist
24418213,"The article did not provide information on the mechanism of action or target of the chemical reaction for aripiprazole or risperidone. However, both drugs are classified as antipsychotic agents and are known to interact with dopamine receptors in the brain.",Agonist
29901250,The drug being evaluated in the study is citicoline (CDP-choline). There is no information provided about the specific receptors targeted by citicoline.,Agonist
11236073,"The receptor(s) are: 5-HT2A, 5-HT3, and alpha 2. The subtype(s) are: N/A. The binding mode(s) are: antagonist and indirect agonist. Therefore the mechanism of action is: antidepressant with antagonist properties at 5-HT2A, 5-HT3, and alpha 2 receptors as well as indirect 5-HT1a agonist effects.",Agonist
7916543,The receptor(s) are: dopamine autoreceptor. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine autoreceptor agonist.,Agonist
17306313,The mechanism of action is: indirect serotonergic agonist. The receptor(s) are: serotonin (5-HT). The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: indirect serotonin agonist.,Agonist
24655473,There are no drugs being evaluated in this study as it is investigating the efficacy and safety of electronic cigarettes in schizophrenic smokers.,Agonist
22645252,"The article is not discussing the evaluation of a specific drug, but rather the effects of dopaminergic modulation on cortico-subcortical network connectivity in healthy individuals. Therefore there is no relevant answer to this question.",Agonist
1411327,"There are no drugs being evaluated in this study, therefore there are no mechanisms of action or receptor subtypes mentioned.",Agonist
29194917,The receptor(s) are: GLP-1. The subtype(s) are: receptor agonists (specifically exenatide). The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonist.,Agonist
1332094,"The mechanism of action is: serotonin receptor responsivity. The receptor(s) are: serotonin (5-hydroxytryptamine; 5HT) receptors. The subtype(s) are not specified. The binding mode(s) are: agonist. Therefore, MCPP is an agonist for serotonin receptors.",Agonist
21847569,The receptor(s) are: metabotropic glutamate. The subtype(s) are: mGlu₂/₃. The binding mode(s) are: agonist. Therefore the mechanism of action is: selective mGlu₂/₃ receptor agonist.,Agonist
23756608,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: dopamine-enhancing partial agonist.,Agonist
10849191,The receptor(s) are: adenosine and dopamine. The subtype(s) are: A2A and D2. The binding mode(s) are: uptake inhibitor. Therefore the mechanism of action is: adenosine uptake inhibitor.,Agonist
24667381,The mechanism of action is glucagon-like peptide-1 (GLP-1) receptor agonist. The receptor subtype is GLP-1 receptor.,Agonist
27956009,"The drug being evaluated in the study is varenicline, which is a nicotinic agonist. The target of the chemical reaction is the nicotinic acetylcholine receptor.",Agonist
2853397,"The drug being evaluated is baclofen, which is a direct GABA agonist. The receptor subtype being targeted is GABA-A. Therefore, the mechanism of action is GABA-A receptor agonism.",Agonist
32403118,"The mechanism of action is targeting the metabotropic glutamate receptor 2/3 (mGluR2/3) agonists. There are two drugs being evaluated: pomaglumetad and TS-134, both of which are mGluR2/3 agonists.",Agonist
10784481,The mechanism of action is glycine. The receptor subtype(s) are: glycine site agonists.,Agonist
17767166,The receptor(s) are: metabotropic glutamate 2/3 (mGlu2/3). The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors.,Agonist
22341370,"The mechanism of action is the endocannabinoid system, and the drug being evaluated is Δ9-tetrahydrocannabinol, which is an eCB agonist. There are not specific receptor subtypes mentioned in the abstract.",Agonist
33501595,The mechanism of action is the activation of the cannabinoid receptor. The article does not specify the subtype(s) of the receptor being evaluated.,Agonist
15602112,The receptor(s) are: serotonin. The subtype(s) are: 5-HT1D. The binding mode(s) are: agonist. Therefore the mechanism of action is: selective 5-HT1D agonist.,Agonist
1751620,"The drug being evaluated is m-chlorophenylpiperazine (MCPP), which is a serotonin (5-hydroxytryptamine, 5HT) agonist. The receptor(s) being targeted are 5HT receptors, but the specific subtype(s) are not mentioned in the article. Therefore, the mechanism of action is a general serotonin agonist.",Agonist
24399553,The receptor(s) are: nicotinic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: nicotinic agonist.,Agonist
8343034,"The drugs being evaluated are clozapine and fluphenazine. The mechanism of action is not explicitly mentioned in the article, but both drugs are classified as neuroleptics/antipsychotics and are known to block dopamine receptors. The article specifically explores the effects of these drugs on serotonin function in patients with schizophrenia. The target receptor subtype is the serotonin receptor.",Agonist
16123739,The receptor(s) are: NMDA and serotonin 5-HT2A. The subtype(s) are: N/A. The binding mode(s) are: antagonist for NMDA and agonist for 5-HT2A. Therefore the mechanism of action is: NMDA antagonist and serotonin 5-HT2A agonist.,Agonist
2576322,"There are no drugs being evaluated in this article. There is reference to neuroleptic treatment and caffeine, but the article is focused on the effects of these substances on smooth pursuit eye movements in schizophrenic patients.",Agonist
14732596,"The drug being evaluated is glycine, a glycine site agonist of the N-methyl-D-aspartate (NMDA) receptors. Therefore, the mechanism of action is NMDA receptor activation through glycine binding to its site. There are no specific receptor subtypes mentioned in the article.",Agonist
23694720,"The mechanism of action is a prodrug of metabotropic glutamate 2/3 receptor agonist, LY404039. The receptor subtype(s) are metabotropic glutamate 2/3 receptors. The binding mode(s) are agonist. Therefore the mechanism of action is a metabotropic glutamate 2/3 receptor agonist. Additionally, the article compares the safety and tolerability of LY2140023 with atypical antipsychotic standard of care (SOC), which includes olanzapine, risperidone, or aripiprazole, but does not provide specific information on the receptors targeted by these drugs.",Agonist
15677609,"There is no drug being evaluated in this study, so there is no mechanism of action or receptor subtype mentioned.",Agonist
103114,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: agonist (piribedil) and antagonist (haloperidol). Therefore the mechanism of action is: a combination of dopamine agonist and antagonist leading to potentiation of extrapyramidal side effects.,Agonist
28984746,"The receptor(s) are: dopamine. The subtype(s) are: D2/D3. The binding mode(s) are: partial agonist/antagonist. Therefore the mechanism of action is: dopamine D2/D3 receptor partial agonist/antagonist. Specifically, the drug being evaluated is aripiprazole, which is a dopamine D3-preferring D2/D3 receptor partial agonist.",Agonist
12727131,There are no drugs being evaluated in this article. The study is examining the response of the dopamine and serotonin systems to the administration of the drugs apomorphine and d-fenfluramine in patients with schizophrenia and healthy controls.,Agonist
9050126,"The drugs being evaluated in this study are bromocriptine and haloperidol. Bromocriptine is a dopamine agonist, specifically a D2 receptor agonist, that blocks the growth hormone response. Haloperidol is an antipsychotic medication that works as a dopamine D2 receptor antagonist. Therefore, the mechanism of action for bromocriptine is D2 receptor agonist and GH response blocker, and for haloperidol is dopamine D2 receptor antagonist.",Agonist
20495134,The receptor(s) are: alpha7 nicotinic acetylcholine receptor. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: selective alpha7 neuronal nicotinic receptor agonist.,Agonist
15232337,The receptor(s) are: opioid. The subtype(s) are: N/A. The binding mode(s) are: antagonist. Therefore the mechanism of action is opioid antagonist.,Agonist
20860881,"The drug being evaluated in the article is risperidone, which acts as an antagonist to dopamine D2 receptors. The receptor subtype is D2, and the binding mode is antagonist.",Agonist
18480682,"The drug(s) being evaluated in this study are: Peony-Glycyrrhiza Decoction (PGD) and bromocriptine (BMT). 
There are no specific receptor subtypes mentioned in the article, but PGD is described as a herbal medicine with suppressive effects on prolactin (PRL) hyperactivities. BMT is a dopamine agonist that is widely used for PRL-secreting disorders. The mechanism of action for PGD is likely multifaceted due to its nature as an herbal preparation. Bromocriptine targets dopamine receptors. Therefore, the mechanism of action for each drug is: herbal medicine with suppressive effects on prolactin hyperactivities and dopamine agonist.",Agonist
15050867,"The article does not mention any drugs being evaluated, but it does discuss the effects of nicotine on brain function in schizophrenia patients.",Agonist
12372663,"The drug being evaluated is nicotine, which targets neuronal nicotinic receptors. The subtype(s) are alpha-7 nicotinic receptors. The binding mode(s) are agonist. Therefore the mechanism of action is: agonist of alpha-7 nicotinic receptors.",Agonist
11763004,"The drug being evaluated is olanzapine. The receptor being targeted is serotonin. The subtype being targeted is 5-HT2c. The binding mode is antagonist. Therefore, the mechanism of action of olanzapine is 5-HT2c antagonist.",Agonist
347574,The receptor(s) are: dopamine. The subtype(s) are not specified. The binding mode(s) is: agonist. Therefore the mechanism of action is dopamine receptor agonist.,Agonist
36104267,"The mechanism of action is DAAO (d-amino acid oxidase) inhibition, which leads to the elevation of d-serine levels and enhances NMDAR (N-methyl-d-aspartate receptor) functions. The drug being evaluated is sodium benzoate, which is a DAAO inhibitor. There is no specific receptor subtype mentioned in the article.",Agonist
16275807,The mechanism of action is NMDA receptor-enhancing agents. The receptor subtype(s) are: NMDA-glycine site agonists and glycine transporter-1 inhibitors. The specific drugs being evaluated are: sarcosine and D-serine as glycine transporter-1 inhibitors.,Agonist
16780811,"The mechanism of action is a Glycine transporter I inhibitor, specifically N-methylglycine (sarcosine). The target of the chemical reaction is the Glycine plasma membrane transport proteins which are being inhibited. Therefore, the receptor subtype(s) are GlyT-1.",Agonist
11166518,"The article is not discussing the evaluation of drugs, but rather studying the relationship between the cortisol response to apomorphine and treatment response in patients with schizophrenia. There are no drugs being evaluated with specific mechanisms of action or receptor subtypes mentioned.",Agonist
18272020,The receptor(s) are: mu-opioid. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: mu-opioid receptor agonist.,Agonist
18649072,The receptor(s) are: NMDA and serotonin. The subtype(s) are: NMDA antagonist and 5-HT2A agonist. The binding mode(s) are: antagonist and agonist. Therefore the mechanism of action is: NMDA antagonist and serotonin 5-HT2A agonist.,Agonist
26839321,"The receptor(s) are: dopamine, serotonin, and histamine-H1. The subtype(s) are: N/A. The binding mode(s) are: antagonist for olanzapine and agonist for betahistine at histamine-H1 receptors. Therefore, the mechanism of action is: betahistine as a centrally acting histamine-H1 agonist reduces olanzapine's effect on histamine receptors in the brain, leading to a decrease in olanzapine-induced weight gain and somnolence.",Agonist
11904128,"The drug being evaluated is donepezil. The mechanism of action is cholinesterase inhibition. The target of this chemical reaction is the breakdown of acetylcholine in the synaptic cleft. The receptor subtype(s) are nicotinic receptors, which are potentiated by allosteric ligands in an alternative treatment approach.",Agonist
22153972,The receptor(s) are: dopamine. The subtype(s) are: D3. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine D3-agonist.,Agonist
23059159,The receptor(s) are: dopamine and GABA. The subtype(s) are: D2 and GABA. The binding mode(s) are: antagonist (dopamine) and agonist (GABA). Therefore the mechanism of action is: dopamine antagonism combined with GABA agonist activity.,Agonist
16192841,The receptor(s) are: NMDA and dopamine. The subtype(s) are: N/A for NMDA and N/A for dopamine agonist. The binding mode(s) are: NMDA modulator and agonist for dopamine. Therefore the mechanism of action is: glutaminergic NMDA modulator and dopamine agonist.,Agonist
7831445,The receptor(s) are: serotonin. The subtype(s) are: 5HT1c. The binding mode(s) are: antagonist. Therefore the mechanism of action is: functional 5HT1c antagonist. The drugs being evaluated are haloperidol and clozapine.,Agonist
9193736,"The drug being evaluated is metachlorophenylpiperazine (m-CPP), which is a direct-acting postsynaptic serotonergic agonist. The mechanism of action is targeting serotonergic receptors. The subtype(s) of the receptor(s) are not specified in the article, but the drug is specifically mentioned as targeting central serotonergic receptors.",Agonist
2884555,The receptor(s) are: dopamine. The subtype(s) are: autoreceptor. The binding mode(s) are: antagonist. Therefore the mechanism of action is dopamine autoreceptor blockade.,Agonist
11302566,There are no drugs being evaluated in this article. The article discusses the measurement of dopamine receptor sensitivity and its correlation with psychopathological symptoms in various neuropsychiatric diseases.,Agonist
8959286,"There are no drugs being evaluated in this article, therefore there are no mechanism of action(s) or receptor subtype(s) to identify. This is a study on potential confounding effects of diet, caffeine, nicotine, and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia.",Agonist
3034188,"The drug(s) being evaluated are gamma-vinyl gamma-aminobutyric acid (GVG) and 4,5,6,7-tetrahydroisoxazolo-(5,4-c) pyridine-3-ol (THIP). The receptor(s) are: GABA-A. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: GABA agonist.",Agonist
21346001,"The drug being evaluated is pergolide, a dopamine agonist. The receptor being targeted is dopamine. The subtype(s) are not specified in the abstract. The binding mode is agonist. Therefore, the mechanism of action is dopamine agonist.",Agonist
11769825,The receptor(s) are: glutamate. The subtype(s) are: kainate/alpha-amino-3-hydroxy-5-methyl-4-isoxazolaproprionate and GABA. The binding mode(s) are: inhibitor for lamotrigine and antagonist/potentiator for topiramate. Therefore the mechanism of action is: glutamate excess release inhibitor for lamotrigine and glutamate kainate/alpha-amino-3-hydroxy-5-methyl-4-isoxazolaproprionate antagonist that potentiates GABA function for topiramate.,Agonist
9169302,The mechanism of action is not clearly stated in the article. Inositol is a simple polyol precursor in a second messenger system important in the brain.,Agonist
30374965,The mechanism of action is glucagon-like peptide-1 receptor agonist. The receptor subtype(s) are: GLP-1. The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonist.,Agonist
23145385,The receptor(s) are: nicotinic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: nicotinic agonist.,Agonist
9952072,The receptor(s) are: sigma. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: sigma receptor agonist.,Agonist
209757,"There are no drugs being evaluated in this article, so there are no mechanism of action(s) or receptor subtype(s) mentioned.",Agonist
21901316,"The mechanism of action is the selective kappa opioid receptor agonist. The receptor subtype is the opioid receptor, specifically the kappa subtype.",Agonist
15309376,The receptor(s) are: NMDA glutamate and group II metabotropic glutamate. The subtype(s) are: N/A. The binding mode(s) are: antagonist for NMDA glutamate receptor and agonist for group II metabotropic glutamate receptor. Therefore the mechanism of action is: attenuation of the disruptive effects of NMDA glutamate receptor antagonist on working memory by pretreatment with group II metabotropic glutamate receptor agonist.,Agonist
22030715,"The drugs being evaluated are S-ketamine and psilocybin. The receptor(s) for S-ketamine are N-methyl-D-aspartate receptors (NMDAR) and for psilocybin are 5-hydroxytryptamine2A receptors (5-HT(2A)R). The binding mode(s) for S-ketamine are antagonist and for psilocybin are agonist. Therefore, the mechanism of action for S-ketamine is NMDAR antagonist and for psilocybin is 5-HT(2A)R agonist.",Agonist
23661634,The drug(s) being evaluated are a dopaminergic agonist (L-dopa) and a dopaminergic antagonist (haloperidol). The receptor(s) are: dopamine. The subtype(s) are not specified in the article. The binding mode(s) are: agonist for L-dopa and antagonist for haloperidol. Therefore the mechanism of action is: dopaminergic agonist and antagonist.,Agonist
19959243,The receptor(s) are: alpha-7 nicotinic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: alpha-7 nicotinic receptor agonist.,Agonist
18506387,"The drug being evaluated is apomorphine, a dopamine receptor agonist. The receptor subtype being targeted is not specified in the abstract.",Agonist
22167235,"There is no mention of any drug(s) being evaluated in this article. Instead, the article discusses the development of a new method to study dopaminergic neurotransmission using positron emission tomography (PET) with [1-(11)C]arachidonic acid as a marker of signal transduction coupled to cytosolic phospholipase A(2) (cPLA(2)). The study measures regional incorporation coefficients K(*) for AA and regional cerebral blood flow (rCBF) in response to the D(1)/D(2) agonist apomorphine in healthy male volunteers. The article postulates that [1-(11)C]AA PET may be useful for studying disturbances of dopaminergic neurotransmission in conditions such as Parkinson's disease and schizophrenia.",Agonist
10509182,"The drug being evaluated is dextroamphetamine, which is a central nervous system stimulant and a dopamine agent. The mechanism of action is to increase levels of dopamine and other monoamines in the brain. The article does not specify the receptor subtype targeted by dextroamphetamine.",Agonist
24099637,The drug(s) being evaluated are: levodopa and haloperidol. The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: agonist (levodopa) and antagonist (haloperidol). Therefore the mechanism of action is: dopamine agonist (levodopa) and dopamine antagonist (haloperidol).,Agonist
16478755,"For l-dopa, the mechanism of action is to act as a precursor of dopamine. The receptor subtype is not specified in the article. For bromocriptine, the mechanism of action is as a D2 agonist. The receptor subtype is D2.",Agonist
27028981,The receptor(s) are: histamine H1. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: histamine H1 receptor agonist.,Agonist
14997272,The drug being evaluated is nicotine. The receptor subtype(s) it targets are nicotinic acetylcholine receptors. The mechanism of action is a nicotinic partial agonist.,Agonist
16342002,The receptor(s) are: serotonin 5-HT2A and glutamate N-methyl-D-aspartate (NMDA). The subtype(s) are: N/A. The binding mode(s) are: agonist and antagonist respectively. Therefore the mechanism of action is: serotonin 5-HT2A agonist and glutamate N-methyl-D-aspartate (NMDA) antagonist.,Agonist
8532820,"The drug being evaluated is apomorphine, which is a dopamine agonist. The receptor subtype being targeted is not specified in the abstract.",Agonist
23936144,"The mechanism of action is the endocannabinoid system, specifically the agonist Δ9-tetrahydrocannabinol (THC). The receptor subtype(s) are the cannabinoid receptors.",Agonist
21956447,"The receptor(s) are: serotonin. The subtype(s) are: 5-HT2A/2C and 5-HT1A. The binding mode(s) are: antagonist (ketanserin) and agonist (psilocybin and psilocin). Therefore the mechanism of action is: ketanserin as a 5-HT2A/2C receptor antagonist attenuates the effects of psilocybin, a serotonergic hallucinogen which acts as a 5-HT2A/2C and 5-HT1A receptor agonist, on automatic and controlled inhibition processes.",Agonist
15358978,"The molecule being evaluated is the 5-HT1A receptor. The study is investigating the occupancy effect of clozapine at the 5-HT1A receptor, but clozapine is not the drug being evaluated in terms of mechanism of action. Therefore, there is no answer to the question regarding the mechanism of action and receptor subtype of the drug being evaluated in this article.",Agonist
23517178,The receptor(s) are: histamine H1 and H3. The subtype(s) are: N/A. The binding mode(s) are: agonist/antagonist. Therefore the mechanism of action is: histamine H3 antagonist/H1 agonist.,Agonist
15983000,"The receptor(s) are: adrenergic alpha. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: adrenergic alpha-agonist. Specifically, clonidine is being evaluated in this study.",Agonist
8914115,The drugs being evaluated are haloperidol and nicotine. The receptor(s) are: dopamine and nicotinic acetylcholine receptors. The subtype(s) are: N/A. The binding mode(s) are: antagonist (haloperidol) and agonist (nicotine). Therefore the mechanism of action is: dopamine receptor antagonist and nicotinic acetylcholine receptor agonist.,Agonist
19304859,"The drugs being evaluated in this study are dimethyltryptamine (DMT) and S-ketamine. The article mentions that DMT is a human 5HT(2A) agonist, while S-ketamine is an N-methyl-D-aspartic acid (NMDA) antagonist. Therefore, the mechanism of action for DMT is as a 5HT(2A) agonist, while the mechanism of action for S-ketamine is as an NMDA antagonist.",Agonist
9871845,The receptor(s) are: alpha and beta adrenergic receptors. The subtype(s) are: N/A. The binding mode(s) are: blocker. Therefore the mechanism of action is: combined alpha- and beta-adrenergic blocker.,Agonist
9160855,The mechanism of action is: alpha2-adrenergic. The receptor subtype(s) are: alpha2-adrenergic. The binding mode(s) are: agonist and antagonist. Therefore the drugs being evaluated are: clonidine (alpha2-adrenergic agonist) and mianserin (alpha2-adrenergic antagonist).,Agonist
30382354,The receptor(s) are: histaminergic. The subtype(s) are not specified but the article states that betahistine is a histaminergic agonist. The binding mode(s) are: agonist. Therefore the mechanism of action is: histaminergic agonist.,Agonist
10187997,The mechanism of action is: Central Nervous System Stimulants. The receptor subtype(s) are: dopamine. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine agonist. The drug being evaluated is methylphenidate.,Agonist
19487625,"The article is not evaluating a drug with a specific mechanism of action or receptor subtype. Rather, it is using positron emission tomography to examine the effects of antipsychotics (clozapine, risperidone, or olanzapine) on the high- and low-affinity states of D2 and D3 receptors. The study also explores the potential therapeutic role of D3 receptors in schizophrenia.",Agonist
25315828,The receptor(s) are: alpha-7 nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: selective alpha-7 nicotinic acetylcholine receptor agonist.,Agonist
29167877,"There is no drug being evaluated in this article. Instead, the article is evaluating the utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders.",Agonist
15173845,"The drug being evaluated in this study is levodopa. The mechanism of action is to increase dopamine availability in the brain. The receptor subtype targeted is the dopamine receptor. However, the specific subtype(s) being affected is not mentioned in the article.",Agonist
23089076,"The mechanism of action is facilitation of NMDA receptor function. The drug being evaluated is glycine, which is a NMDA glycine-site agonist.",Agonist
30306671,"The drug(s) being evaluated in this study are: carbidopa/L-dopa and haloperidol. 
The receptor(s) are: dopamine. The subtype(s) are: D1 and D2. The binding mode(s) are: nonselective dopamine agonist and D2 antagonist. Therefore the mechanism of action is: indirect D1 stimulation via combined nonselective dopamine agonist and D2 antagonist.",Agonist
19154656,"The drug(s) being evaluated are: ketamine and haloperidol. 

For ketamine: 
The receptor(s) are: N-methyl-D-aspartate (NMDA). 
The subtype(s) are: N/A (as NMDA is a specific type of glutamate receptor). 
The binding mode(s) are: antagonist. Therefore the mechanism of action is: NMDA antagonist.

For haloperidol: 
The receptor(s) are: dopamine. 
The subtype(s) are: D2. 
The binding mode(s) are: antagonist. Therefore the mechanism of action is: dopamine D2 antagonist.",Agonist
20921890,"The receptor(s) are: dopamine and serotonin. The subtype(s) are: not specified, but the drug has a strong affinity for dopamine and serotonin receptors. The binding mode(s) are: agonist for GABA(A) and not specified for dopamine and serotonin receptors. Therefore, the mechanism of action is: a gamma aminobutyric acid (GABA) ester of perphenazine with strong affinity for dopamine and serotonin receptors, and agonist activity at GABA(A) receptors.",Agonist
31773210,"The drug being evaluated is F17464. The receptor(s) are: dopamine. The subtype(s) are: D3 and D2. The binding mode(s) are: antagonist. Therefore, the mechanism of action is: dopamine D3 receptor antagonist with relatively high D3 selectivity.",Agonist
16603132,The receptor(s) are: dopamine. The subtype(s) are: D1/D2. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine D1/D2 agonist (specifically pergolide).,Agonist
24612097,"The drug being evaluated is sarcosine, which is a glycine transporter I inhibitor. The target of the chemical reaction is the N-methyl-D-aspartate (NMDA) receptor glycine site. Therefore, the mechanism of action is the enhancement of the NMDA receptor-glycine cascade. There are no specific receptor subtypes mentioned in this article.",Agonist
9826114,"The receptor(s) are: dopamine. The subtype(s) are: D3 and autoreceptors. The binding mode(s) are: antagonist. Therefore, the mechanism of action is: D3 and autoreceptor-preferring dopamine antagonist.",Agonist
16806095,"The receptor(s) are: acetylcholinesterase. The subtype(s) are: N/A. The binding mode(s) are: inhibitor. Therefore, the mechanism of action is cholinesterase inhibitor with putative nicotinic agonist-like effects.",Agonist
30654644,"The mechanism of action is adrenergic alpha-2 receptor agonist, and the receptor subtype is alpha-2 adrenergic receptor. The drug being evaluated is guanfacine.",Agonist
21315807,There is no drug being evaluated in this study. The article describes the role of dopamine transporter gene expression and nicotine on P50 sensory gating in healthy individuals with varying genetic expression of the dopamine transporter.,Agonist
32087425,The receptor(s) are: glucagon-like-peptide-1 (GLP-1). The subtype(s) are: GLP-1 receptor agonist. The binding mode(s) are: agonist. Therefore the mechanism of action is: GLP-1 receptor agonist.,Agonist
3517082,"The mechanism of action for clonidine is binding to and activating alpha-2 adrenergic receptors, leading to decreased sympathetic activity. The article does not specify any other receptor subtypes being evaluated with clonidine.",Agonist
31283908,"The mechanism of action(s) and receptor subtype(s) are: 
- Cannabinoid receptor agonists: CB1 receptor
- Nicotinic receptor agonists: Nicotinic acetylcholine receptor (nAChR) 
The binding mode(s) are not specified in the abstract.",Agonist
17952411,None,Agonist
19961902,"The drug being evaluated in the study is nicotine, which targets nicotinic receptors. The article also discusses the influence of dopamine D2 receptor gene polymorphisms on P50 and its inhibition during nicotine administration. Therefore, the receptors being evaluated are nicotinic receptors and dopamine D2 receptors. The binding mode for nicotine is agonist.",Agonist
18037816,"The drug being evaluated here is nicotine, which binds to nicotinic receptors. There is no specific subtype mentioned in the article. Therefore, the mechanism of action is nicotinic receptor agonist.",Agonist
19556112,The article is not investigating a drug or evaluating a mechanism of action or receptor subtype. It is studying the effects of oral glycine administration on brain glycine/creatine ratios in healthy men using proton magnetic resonance spectroscopy.,Agonist
33196868,The receptor(s) are: dopamine. The subtype(s) are: D2/D3. The binding mode(s) are: agonist/partial agonist. Therefore the mechanism of action is: D2/D3 receptor agonist/partial agonist.,Agonist
18579575,"There are no drugs being evaluated in this article, so there are no mechanism of action(s) or receptor subtype(s) to identify.",Agonist
23744798,"The drug being evaluated is nicotine, which is a nicotinic agonist. The target receptors are nicotinic receptors.",Agonist
7991724,"There are no drugs being evaluated in this article, so there are no target receptors or mechanisms of action discussed.",Agonist
27237598,"The drugs being evaluated in this study are transdermal nicotine patches and varenicline. The mechanism of action of transdermal nicotine patches is to deliver nicotine through the skin to help reduce cravings and withdrawal symptoms associated with nicotine addiction. Varenicline works by binding to nicotine receptors in the brain, reducing the pleasurable effects of smoking and decreasing the severity of withdrawal symptoms. Therefore, the target of the chemical reaction for transdermal nicotine patches is nicotine receptors, and for varenicline, it is also nicotine receptors. However, the specific receptor subtype(s) are not mentioned in the article.",Agonist
18611293,"There are no specific drugs mentioned in this article. Therefore, there is no information available to answer this question.",Agonist
8968299,"The drug being evaluated is ephedrine, which is an alpha-adrenergic agonist. The receptor subtype(s) targeted by the drug are alpha-adrenergic receptors.",Agonist
8102552,The mechanism of action for selegiline is selective monoamine oxidase B inhibitor and antioxidant. There is no specific receptor subtype mentioned in the article.,Agonist
18261886,The article does not mention the mechanism of action or receptor subtype of the drug olanzapine. The study is focused on the analysis of D-serine and glycine concentrations in cerebrospinal fluid in schizophrenic patients and how they are affected by olanzapine therapy.,Agonist
23535252,"There are no drugs being directly evaluated in this article. The study looks at the effects of nicotine and how it modulates sensory gating and cognitive processing based on the COMT genotype. The study also calculates the enzymatic activity of COMT, which is responsible for regulating dopamine levels in the brain. Therefore, the mechanism of action in this study relates to the genetic variation in COMT and its impact on the dopaminergic system.",Agonist
20973856,"There are multiple drugs mentioned in the article and their mechanisms of action are not the focus of the study. Bupropion SR and nicotine replacement therapies (patch and lozenge) are mentioned as smoking cessation pharmacotherapies, but the article does not specify their mechanisms of action or receptor subtypes targeted.",Agonist
8794491,The receptor(s) are: dopamine and norepinephrine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is dopamine and norepinephrine agonist.,Agonist
17976537,"The mechanism of action is: nicotine, a nicotinic agonist. The receptor subtype is: nicotinic receptors.",Agonist
29076028,"The drug being evaluated is BI 425809, which is a GlyT1 inhibitor targeting glycine transporter 1. There is no specific receptor subtype mentioned in the article. Therefore, the mechanism of action is inhibiting glycine transport to improve NMDA receptor hypofunction.",Agonist
29846887,"The receptor(s) are: glycine transporter 1 and N-methyl-D-aspartate (NMDA) receptor. The subtype(s) are: N/A. The binding mode(s) are: inhibitor. Therefore the mechanism of action is: glycine transporter 1 inhibitor, potentially improving NMDA receptor function.",Agonist
29302713,"The mechanism of action and receptor subtype(s) of psilocybin are not explicitly stated in the article. However, it is mentioned that psilocybin is a psychedelic with 5-HT (serotonin) activity.",Agonist
22451196,The receptor(s) are: dopamine and serotonin. The subtype(s) are: D3/D2 and 5-HT1A. The binding mode(s) are: partial agonist. Therefore the mechanism of action is: dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist.,Agonist
15261701,"The drug being evaluated in the study is bromocriptine, which is a dopamine D2 receptor agonist. The mechanism of action is therefore D2 receptor agonist.",Agonist
8888383,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: indirect agonist. Therefore the mechanism of action is indirect dopamine agonist. The drugs being evaluated with are amphetamine and nicotine.,Agonist
15358983,The receptor(s) are: dopamine D2. The subtype(s) are: N/A. The binding mode(s) are: precursor and agonist. Therefore the mechanism of action is: dopamine precursor (L-dopa) and dopamine D2 receptor agonist (bromocriptine).,Agonist
19026256,The article does not mention a specific mechanism of action or receptor subtype for ziprasidone.,Agonist
3534900,The receptor(s) are: a2-adrenergic. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: a2-adrenergic receptor agonist.,Agonist
8731458,"There are no drugs being evaluated in this article. The article discusses the intracellular calcium responses to serotonin in patients with depression, schizophrenia, and substance abuse.",Agonist
8394651,"The drug being evaluated is clozapine, which is a potent serotonin antagonist. The receptor subtype being targeted is the serotonin receptor. The specific subtype(s) are not mentioned in the article.",Agonist
8642546,"The mechanism of action is related to inositol metabolism involved in the second messenger system for several muscarinic cholinergic receptors. However, there is no specific drug being evaluated in this study.",Agonist
3209717,"The drugs being evaluated in this article are: a dopamine agonist (bromocriptine), a dopamine antagonist (haloperidol), a cholinergic agonist (physostigmine), and a cholinergic antagonist (benztropine). The mechanism of action and receptor subtypes vary depending on the drug. Bromocriptine targets dopamine receptors as an agonist. Haloperidol targets dopamine receptors as an antagonist. Physostigmine targets cholinergic receptors as an agonist. Benztropine targets cholinergic receptors as an antagonist.",Agonist
23785166,The receptor(s) are: serotonin. The subtype(s) are: 5-HT2A. The binding mode(s) are: agonist for psilocybin and antagonist for ketanserin. Therefore the mechanism of action for psilocybin is: serotonin 5-HT2A receptor agonist. The mechanism of action for ketanserin is: selective antagonist of 5-HT2A receptors.,Agonist
15009821,The mechanism of action is dopamine agonist. The receptor subtype(s) are dopamine receptors.,Agonist
12212663,"The drugs being evaluated in this study are clonidine and yohimbine, both of which are alpha2 noradrenergic agents. The receptor subtype being targeted is the alpha2 adrenergic receptor. The binding mode is not explicitly stated in the abstract, but clonidine is known to be an agonist and yohimbine an antagonist of this receptor subtype. The overall mechanism of action is therefore: alpha2 adrenergic receptor agonist/antagonist.",Agonist
16614537,"The drug(s) being evaluated in this study are vitamin B6 and mianserin. However, the article does not provide information on the specific receptor subtype(s) or mechanism(s) of action targeted by these drugs.",Agonist
3049101,The receptor(s) are: dopamine. The subtype(s) are: mixed agonistic/antagonistic (not specified). The binding mode(s) are: mixed agonistic/antagonistic. Therefore the mechanism of action is: dopamine mixed agonistic/antagonistic.,Agonist
10836287,The drug being evaluated is ipatropium bromide (IPB) and its mechanism of action is a muscarinic antagonist. The target of the chemical reaction is acetylcholine receptors in salivary glands. There are no specific receptor subtypes mentioned in this article.,Agonist
11814535,The receptor(s) are: serotonin. The subtype(s) are: mixed 5-HT. The binding mode(s) are: agonist/antagonist. Therefore the mechanism of action is: mixed 5-HT receptor agonist/antagonist.,Agonist
15554771,"The drug being evaluated is vitamin B6, which does not act on a specific receptor subtype or involve a chemical reaction. It is a dietary supplement that has been found to be effective in the treatment of neuroleptic-induced movement disorders.",Agonist
16195121,"The receptor(s) are: dopamine and serotonin. The subtype(s) are: N/A. The binding mode(s) are: N/A. The drugs being evaluated are: olanzapine, risperidone, perphenazine, and buspirone. Therefore, the mechanism of action is not clear and may involve multiple receptors and binding modes.",Agonist
9593104,"The drug being evaluated in this study is ketamine, which is an NMDA receptor antagonist. The receptor(s) being targeted are the glutamatergic N-methyl-d-aspartate (NMDA) receptors. The mechanism of action is NMDA receptor antagonism.",Agonist
10367553,"The mechanism of action is serotonin releaser, and the target receptor subtype(s) are not specified.",Agonist
10192823,"The drug being evaluated is psilocybin, which is a mixed 5-HT2A and 5-HT1A receptor agonist. The mechanism of action is the stimulation of both 5-HT2A and 5-HT1A receptors, which may be important for the modulation of striatal dopamine release in acute psychoses. Psilocybin does not have a specific binding mode with a receptor subtype, but rather stimulates both 5-HT2A and 5-HT1A receptors.",Agonist
20643194,The article does not mention any drugs being evaluated. It discusses the effects of nicotine on P50 amplitude and sensory gating in healthy non-smokers.,Agonist
9084066,"The receptor(s) are: dopamine. The subtype(s) are: non-selective. The binding mode(s) are: agonist for d-amphetamine and antagonist for haloperidol. Therefore, the mechanism of action for d-amphetamine is an indirect dopamine agonist, and the mechanism of action for haloperidol is a non-selective dopamine receptor antagonist.",Agonist
1681560,The mechanism of action is: sigma receptor antagonism. The receptor subtype(s): sigma receptors. The binding mode(s) are: antagonist. Therefore the mechanism of action is sigma receptor antagonist.,Agonist
9862082,The receptor(s) are: dopamine. The subtype(s) are: non-selective dopamine receptor and indirect dopamine-agonist. The binding mode(s) are: antagonist for haloperidol and agonist for d-amphetamine. Therefore the mechanism of action for haloperidol is: non-selective dopamine receptor antagonist and for d-amphetamine is: indirect dopamine-agonist.,Agonist
2574194,The receptor(s) are: dopamine. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine receptor agonist.,Agonist
8741023,The receptor(s) are: opiate sigma. The subtype(s) are: N/A. The binding mode(s) are: antagonist. Therefore the mechanism of action is: opiate sigma-receptor antagonist.,Agonist
7831432,"The drug being evaluated is clozapine, an atypical antipsychotic. The receptors being targeted are dopamine D2 receptors and serotonin 5-HT2 receptors.",Agonist
8290671,"The article does not mention any drugs being evaluated. Instead, it discusses the relationship between GABAergic dysfunction and saccadic eye movement abnormalities in schizophrenic patients with tardive dyskinesia.",Agonist
2643996,"The receptor(s) are: dopamine. The subtype(s) are: D2 (not explicitly stated, but bromocriptine is known to be a D2 receptor agonist). The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine D2 agonist.",Agonist
1358119,The receptor(s) are: dopamine autoreceptors. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: dopamine autoreceptor agonist.,Agonist
11817518,The mechanism of action is: Adrenergic alpha-Agonist. The target of the chemical reaction is: alpha-adrenergic receptors. The subtype(s) are: N/A. The binding mode(s) are: agonist. Therefore the mechanism of action is: Adrenergic alpha-Agonist.,Agonist
15093958,"The mechanism of action(s) and receptor subtype(s) being evaluated are related to nicotine and nicotinic agonists. The article does not specify the exact receptor subtype(s) being targeted. Therefore, the mechanism of action can be considered as nicotinic agonist.",Agonist
16896958,The article does not discuss the evaluation of any drug(s) with specific mechanism of action(s) or receptor subtype(s). It only explores the effect of nicotine on antisaccade performance.,Agonist
32791894,The article does not provide information on the mechanism of action or receptor subtypes of olanzapine or samidorphan.,Antagonist
35211743,"The mechanism of action is: antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors. The receptor subtype(s) are: 5-HT2A, sigma2, and α1A-adrenergic. Therefore the drug being evaluated targets these receptors as antagonists.",Antagonist
33610228,The mechanism of action is the inhibition of glycine transporter-1. There are no specific receptor subtypes mentioned in this article.,Antagonist
34015555,The article does not provide information on the mechanism of action or receptor subtype for the combination of olanzapine and samidorphan.,Antagonist
32141723,"The article does not provide information about the specific mechanism of action or receptor subtype for olanzapine and samidorphan. However, both drugs are antipsychotics used to treat schizophrenia. Olanzapine is a second-generation (atypical) antipsychotic that blocks dopamine and serotonin receptors in the brain. Samidorphan is an opioid antagonist that works by preventing the activation of opioid receptors in the brain, which is thought to reduce the risk of addiction and abuse associated with olanzapine.",Antagonist
35422467,"The drug being evaluated is ketamine, an NMDA receptor antagonist. There is no mention of receptor subtype(s) specifically in this article.",Antagonist
16678390,The receptor(s) are: nicotinic acetylcholine. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: nicotinic acetylcholine receptor antagonist (mecamylamine).,Antagonist
9193198,The receptor(s) are: D4 dopamine. The subtype(s) are: N/A. The binding mode is: selective antagonist. Therefore the mechanism of action is: D4 dopamine receptor antagonist.,Antagonist
30822774,The mechanism of action is: D3 receptor antagonist. The receptor subtype(s) are: D3 dopamine receptors. Therefore the drug being evaluated is a preferential D3 antagonist.,Antagonist
24525659,"The drug being evaluated is AZD2624, a selective, orally active neurokinin 3 (NK(3)) receptor antagonist. Therefore, the mechanism of action is: NK(3) receptor antagonist.",Antagonist
15820238,"The drug being evaluated is mecamylamine, which is a nicotinic acetylcholine receptor antagonist. The subtype(s) are not specified in the abstract.",Antagonist
37596,The article discusses the role of endorphins in schizophrenia and the use of narcotic antagonists to test the hypothesis and potentially treat schizophrenia symptoms. It does not specifically mention any mechanism of action or receptor subtype for the narcotic antagonists being evaluated.,Antagonist
7527327,The mechanism of action is a combination of potent serotonin (5-hydroxytryptamine) 5-HT2 and dopamine D2 receptor antagonism. The receptor subtype(s) are: 5-HT2 and D2 receptors.,Antagonist
15023570,The mechanism of action is selective antagonism of the dopamine D4 receptor. The receptor subtype being evaluated is the dopamine D4 receptor.,Antagonist
24516190,The mechanism of action is histamine H3 receptor antagonist. The subtype(s) are H3 receptors. The drug being evaluated is ABT-288.,Antagonist
25728831,The mechanism of action is histamine H₃ receptor antagonist. The target of the chemical reaction is the histamine H₃ receptor. The subtype(s) are not specified in the abstract.,Antagonist
18801405,The receptor(s) are: 5HT2A/2C. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: 5HT2A/2C receptor antagonist.,Antagonist
18692175,The mechanism of action is: vasopressin V2-receptor antagonist. The receptor subtype is: V2-receptor. The drug being evaluated is tolvaptan.,Antagonist
21346607,The mechanism of action is dopamine D3 receptor antagonism. The receptor subtype is the dopamine D3 receptor.,Antagonist
30845818,"The drug being evaluated is samidorphan, which is an opioid antagonist. The target of the chemical reaction is the opioid receptors. The subtype(s) of opioid receptors involved are not specified in the article.",Antagonist
22299296,The mechanism of action is: serotonin and dopamine receptor antagonist. The specific receptor subtypes are: serotonin 5-HT2A and dopamine D2 receptors. The drug being evaluated is risperidone.,Antagonist
10080558,The mechanism of action is: antagonist at the D4 and serotonin2A (5-HT2A) receptors. The receptor subtype(s) are: D4 and 5-HT2A. The drug being evaluated is fananserin.,Antagonist
7902766,"The mechanism of action is: selective 5-HT2 and 5-HT1c antagonist. The receptor subtype(s) are: 5-HT2 and 5-HT1c. Therefore, the drug is a selective serotonin receptor antagonist.",Antagonist
22995972,The article did not provide specific information on the mechanism of action or receptor subtype targeted by JNJ-37822681.,Antagonist
24215171,The mechanism of action is: H3 receptor antagonist. The receptor subtype is: H3.,Antagonist
23926573,The drug JNJ-37822681 is a fast-dissociating D2 receptor antagonist. The binding mode is antagonism of the D2 receptor subtype of dopamine receptors.,Antagonist
8584612,The mechanism of action is: D1-dopamine receptor antagonist. The receptor subtype is: dopamine D1 receptor.,Antagonist
21192149,The receptor(s) are: cannabinoid-1. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: cannabinoid-1 receptor antagonist.,Antagonist
30359166,The mechanism of action is: serotonin 3 receptor antagonist. The subtype(s) are: N/A. Therefore the drug is evaluated as a serotonin 3 receptor antagonist.,Antagonist
15927092,"There are no drugs being evaluated in this article, so there is no mechanism of action or receptor subtype information to provide.",Antagonist
18789844,The mechanism of action is a 5-HT3 receptor antagonist. The receptor subtype is 5-hydroxytryptamine 3 (5-HT3) receptor. Therefore the mechanism of action is a 5-HT3 receptor antagonist.,Antagonist
10484947,The article does not provide information on the mechanism of action or receptor subtype targeted by risperidone or haloperidol.,Antagonist
27048954,"The drug being evaluated is memantine, which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The target of the chemical reaction is the NMDA receptor.",Antagonist
19700263,"The drug being evaluated is mecamylamine, which is a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist. The mechanism of action is antagonism of high-affinity nAChRs, which prompts compensatory smoking, increasing the intensity of smoking and nicotine exposure without alleviating craving. The receptor subtype(s) are not specified in the abstract.",Antagonist
23768250,The mechanism of action being evaluated is the selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173). The receptor subtype being targeted is the 5HT6 receptor.,Antagonist
32961542,The mechanism of action is: uncompetitive low-affinity NMDA receptor antagonist (memantine). The receptor subtype(s) are: NMDA receptors.,Antagonist
23754735,"The drug being evaluated is JNJ-37822681, which is a selective fast-dissociating dopamine D2-receptor antagonist. Therefore, the mechanism of action is dopamine D2-receptor antagonism. The receptor subtype is dopamine D2.",Antagonist
23532746,"The mechanism of action is T-type calcium channel antagonist. The receptor subtype(s) are calcium channels, specifically the T-type calcium channels.",Antagonist
32340927,The mechanism of action of the drug is as an NMDA antagonist (memantine). The article does not specify receptor subtypes.,Antagonist
12650957,The mechanism of action is: serotonin 5-HT2A antagonist. The receptor subtype is: 5-HT2A. The drug being evaluated is mianserin.,Antagonist
22020346,The mechanism of action is: N-methyl-d-aspartate receptor antagonist (ketamine). The receptor subtype(s) are: NMDA receptors.,Antagonist
23644161,The article does not provide information on any specific drug or receptor subtype that is being evaluated. It discusses the use of phMRI to evaluate the sensitivity of rats treated with phencyclidine (PCP) as a model for schizophrenia.,Antagonist
2886110,There are no drugs being evaluated in this article. The study evaluated the use of a methylphenidate challenge test to predict relapse in schizophrenia patients.,Antagonist
11978847,"The article does not mention any specific drugs or chemical reactions being evaluated. However, it discusses the role of dopamine D1 receptors in the prefrontal cortex and their relationship to working memory deficits in schizophrenia.",Antagonist
23571810,"The drug being evaluated is ABT-925, which is a selective dopamine D3 receptor antagonist. The mechanism of action is blocking the dopamine D3 receptor subtype.",Antagonist
21726104,The mechanism of action for the drug topiramate in this study is as an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist. No receptor subtype(s) are specified.,Antagonist
6134273,The mechanism of action is beta-adrenergic blockade. The receptor subtype(s) are beta-adrenergic receptors.,Antagonist
14643092,The mechanism of action for lamotrigine is as an excitatory amino acid antagonist. The receptor subtype(s) are: N/A.,Antagonist
28556775,The mechanism of action for the drug ketamine is as an NMDA receptor antagonist. The receptor subtype is the NMDA receptor.,Antagonist
28033691,The mechanism of action is: partial uncompetitive NMDA receptor antagonist. The receptor subtype(s) are: NMDA receptors. The drug being evaluated is memantine.,Antagonist
7520904,The mechanism of action(s) are: combined 5-HT2A/D2 antagonist. The receptor subtype(s) are: serotonin 5-HT2A and dopamine D2. Therefore the mechanism of action is: combined antagonist of the serotonin 5-HT2A and dopamine D2 receptors.,Antagonist
25896256,"The mechanism of action is blockage of the N-methyl-D-aspartate (NMDA) receptor via ketamine, which is an NMDA receptor antagonist. The receptor subtype is NMDA.",Antagonist
15169685,"For the neurokinin (NK(3)) antagonist (SR142801): the mechanism of action is neurokinin receptor antagonist, and the receptor subtype is NK(3). 
For the serotonin 2A/2C (5-HT(2A/2C)) antagonist (SR46349B): the mechanism of action is serotonin receptor antagonist, and the receptor subtypes are 5-HT(2A) and 5-HT(2C).
For the central cannabinoid (CB(1)) antagonist (SR141716): the mechanism of action is cannabinoid receptor antagonist, and the receptor subtype is CB(1).
For the neurotensin (NTS(1)) antagonist (SR48692): the mechanism of action is neurotensin receptor antagonist, and the receptor subtype is NTS(1).",Antagonist
2897959,The mechanism of action is beta-adrenoceptor antagonist. The receptor subtype(s) are: beta-1 and beta-2 adrenergic receptors.,Antagonist
17464718,"The mechanism of action of the drug being evaluated in this study is glucocorticoid receptor antagonism, and the drug is mifepristone. There are no receptor subtypes mentioned in the abstract.",Antagonist
17728110,"The mechanism of action is: NMDA receptor antagonist, with a weak non-selective affinity to NMDA receptors. The subtype(s) are: N/A. The drug being evaluated is memantine.",Antagonist
27940324,"The mechanism of action is NMDA receptor antagonism, and the drug is memantine. The receptor subtype is NMDA receptors.",Antagonist
10220013,There are no drugs being evaluated in this article. The article is discussing the association between a genetic polymorphism in the serotonin-2A receptor gene and schizophrenia.,Antagonist
9617985,"The drug being evaluated is naltrexone. The mechanism of action is as a narcotic antagonist. The target of the chemical reaction is not specified in the article, but naltrexone is known to block the effects of opioids by binding to their receptors in the brain. There is no mention of receptor subtypes.",Antagonist
21590281,The receptor(s) are: CB(1) cannabinoid. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: CB(1) cannabinoid receptor antagonist.,Antagonist
24089054,"The mechanism of action is d-amino acid oxidase inhibition, achieved by using the drug sodium benzoate. The target is the metabolism of d-amino acids. There is no specific receptor subtype mentioned in relation to the drug.",Antagonist
10190222,"The article does not provide information on the mechanism of action or receptor subtype(s) of the drugs being evaluated, as it focuses on the efficacy of olanzapine and haloperidol in treating anxious-depressive symptoms in schizophrenia patients.",Antagonist
26343594,"The drugs being evaluated are risperidone and dextromethorphan. The mechanism of action for dextromethorphan is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, which protects monoamine neurons. There is no information provided on the mechanism of action for risperidone. Therefore, there is no information provided on the receptor subtype(s) being targeted.",Antagonist
15023569,"The article is not discussing the evaluation of drugs, but rather the measurement of serotonin-1A receptor binding using positron emission tomography with [carbonyl-(11)C]WAY-100635 in patients with schizophrenia. There is no information about the mechanism of action or receptor subtype of any drugs being evaluated.",Antagonist
10518181,The mechanism of action is N-methyl-D-aspartic acid (NMDA) receptor antagonist and the receptor subtype is NMDA receptors.,Antagonist
26329382,"The mechanism of action of the drug modafinil is not mentioned in the abstract. However, it is mentioned that modafinil modulates catecholamine neurotransmission. Therefore, it may be assumed that it acts as a dopamine and/or norepinephrine reuptake inhibitor. The receptor subtype(s) that may be involved in this mechanism of action are dopamine and norepinephrine transporters.",Antagonist
19005465,The mechanism of action for memantine is as an uncompetitive antagonist of glutamate receptors of the N-methyl-D-aspartate type. The receptor subtype is the NMDA receptor.,Antagonist
15652874,The mechanism of action is: glucocorticoid receptor antagonist. The receptor subtype(s) are: glucocorticoid receptors. The drug being evaluated is mifepristone (RU-486).,Antagonist
9260734,"The article does not provide specific information on the mechanism of action, target of chemical reaction, or receptor subtype(s) that are being evaluated with the use of methylene blue as an adjuvant therapy for schizophrenia.",Antagonist
22389244,"The drug being evaluated is ketamine, a non-competitive NMDA-receptor antagonist. The target of the chemical reaction is the NMDA receptor. The subtype(s) are not specified.",Antagonist
27776560,The mechanism of action of memantine is as an antagonist of N-methyl-D-aspartate (NMDA) receptors. There is no mention of receptor subtypes.,Antagonist
22137462,The receptor(s) are: cannabinoid receptor. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: cannabinoid receptor antagonist (rimonabant).,Antagonist
25980345,"The mechanism of action is: selective estrogen receptor modulator. The receptor subtype(s) are: estrogen receptors. Therefore, the drug being evaluated is raloxifene, which acts as a selective estrogen receptor modulator.",Antagonist
20570110,"The drug being evaluated is celecoxib, which is a cyclooxygenase-2 (COX-2) inhibitor. The mechanism of action is inhibiting the COX-2 enzyme, which is responsible for creating inflammatory substances in the body. There is no receptor subtype mentioned in the article.",Antagonist
28425497,The mechanism of action is: NMDA receptor antagonist. The subtype(s) are: N/A. Therefore the receptor(s) being evaluated are the NMDA receptors.,Antagonist
32160422,"The article does not provide information about the specific mechanism of action or receptor subtype for olanzapine and samidorphan. Olanzapine is an atypical antipsychotic medication that primarily acts as a dopamine and serotonin receptor antagonist, while samidorphan is an opioid antagonist that is being studied as an adjunct therapy for opioid addiction treatment.",Antagonist
2149882,The mechanism of action is selective dopamine D2 antagonism. The receptor subtype is dopamine D2.,Antagonist
29873956,The mechanism of action for MIN-101 is: sigma-2 and 5-HT2A antagonism. There are no mentioned receptor subtypes.,Antagonist
6791204,The receptor(s) are: opiate. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: opiate receptor antagonist.,Antagonist
18334909,"The mechanisms of action for the drugs are not provided in the given abstract. However, it is mentioned that iloperidone is a mixed D2/5-HT2 antagonist, while ziprasidone is used as an active control.",Antagonist
16034443,"The drug in question is ketamine, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Therefore, the mechanism of action is NMDA receptor antagonism. The receptor subtype(s) are NMDA receptors.",Antagonist
9549958,"The mechanism of action is: 5-HT2a/2c, dopamine D1D2D4 antagonist with anticholinergic activity. The receptor subtype(s) are: serotonin (5-HT), dopamine (D1, D2, and D4) and cholinergic (antagonist). The drug being evaluated is olanzapine.",Antagonist
28398342,"There is no specific drug being evaluated in this article, so there is no target of the chemical reaction or receptor subtype mentioned.",Antagonist
15905072,The article does not provide information on the mechanism of action or receptor subtype(s) of the drug (clozapine) being evaluated.,Antagonist
26819282,"The article does not discuss any specific drugs, mechanism of actions or receptor subtypes being evaluated. It focuses on the relationship between frontal D2/3 receptor availability, cognitive functions, and psychopathology in antipsychotic-naïve first-episode schizophrenia patients before and after their first antipsychotic treatment.",Antagonist
21275080,"There are no drugs being evaluated in this article. The focus is on the relationship between tryptophan metabolites, specifically 3-OHKY, and clinical symptoms in patients with schizophrenia.",Antagonist
32393412,The article does not provide information on the mechanism of action or receptor subtype for olanzapine or samidorphan.,Antagonist
18232726,The article does not provide information on the mechanism of action or receptor subtype of olanzapine and clozapine.,Antagonist
22773165,The mechanism of action is: dopamine D₂-receptor antagonist. The receptor subtype is: D₂-receptor.,Antagonist
21302161,The mechanism of action for ketamine is blocking the NMDA receptor. There is no specific receptor subtype identified in the article.,Antagonist
23515583,"The mechanism of action is: 5-HT3 receptor antagonist. The receptor subtype(s) are: 5-HT3. Therefore, the drug being evaluated is tropisetron, a 5-HT3 receptor antagonist.",Antagonist
26691576,"The drug combination being evaluated are a Glycine transporter I (GlyT-1) inhibitor (sarcosine) and a d-amino acid oxidase (DAAO) inhibitor (sodium benzoate). The target of the chemical reaction is the N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission. The receptor subtype(s) are NMDA receptors. Therefore, the mechanism of action is inhibition of DAAO and GlyT-1 to enhance NMDA receptor-mediated neurotransmission.",Antagonist
9510219,The article does not specify the mechanism of action(s) or the receptor subtype(s) for olanzapine or haloperidol.,Antagonist
16959472,"The mechanism of action is: serotonin-3 (5-HT3) receptor antagonist. The receptor subtype(s) is/are: 5-HT3 receptor. Therefore, the drug being evaluated is ondansetron, which is a serotonin-3 (5-HT3) receptor antagonist.",Antagonist
14613676,"The article does not describe the mechanism of action or the receptor subtype of any drugs being used, as the focus is on assessing serotonergic dysfunction in schizophrenia through a physiological measure.",Antagonist
22290266,"The drugs being evaluated in this study are antipsychotic drugs, which target dopamine D2 receptors. The study measures the estimated dopamine D2 receptor occupancy levels of the antipsychotic drugs risperidone, olanzapine, and ziprasidone in patients with schizophrenia. The study does not evaluate the mechanism of action of the drugs themselves, but rather their impact on neurocognitive function in patients. Therefore, there are no specific receptor subtypes or binding modes identified in this study.",Antagonist
18978498,"The article does not provide information on the mechanism of action or receptor subtypes of the drugs (amisulpride, antipsychotics, benzodiazepines, and anticholinergic drugs) mentioned in the study.",Antagonist
16086616,The mechanism of action for topiramate is as a glutamate antagonist. There is no mention of receptor subtypes.,Antagonist
19570929,"The article does not focus on a specific drug or receptor mechanism of action, but rather examines the relationship between serum anticholinergic activity and cognitive performance in schizophrenia patients. Anticholinergic activity is not specific to one receptor subtype or mechanism, but affects the entire cholinergic system by blocking the action of acetylcholine.",Antagonist
23012427,"The drug being evaluated is ketamine, which is an NMDA glutamate receptor antagonist. Therefore, the target of the chemical reaction is the NMDA receptor subtype.",Antagonist
8733795,"The mechanism of action is: alpha 2 adrenergic receptor antagonism. The receptor subtype(s) are: alpha 2 adrenergic receptors. The drug(s) being evaluated are: idazoxan (alpha 2 antagonist) and typical neuroleptics. Clozapine (an atypical neuroleptic) is also mentioned, but is not being directly evaluated in this study.",Antagonist
1978858,"The mechanism of action is: selective antagonist of D2 receptors. The receptor subtype is: D2 receptors. Therefore, the drug sulpiride is being evaluated as a selective D2 receptor antagonist.",Antagonist
11032974,"The drug being evaluated is ketamine, which is a noncompetitive NMDA antagonist. The target of the chemical reaction is NMDA receptors, and the receptor subtype is the glutamatergic N-methyl-D-aspartate (NMDA) receptor. Therefore, the mechanism of action of the drug is the disruption of NMDA transmission.",Antagonist
22717030,The receptor(s) are: N-methyl-D-aspartate (NMDA) and nicotinic acetylcholine (nAChR). The subtype(s) are: N/A. The binding mode(s) are: uncompetitive antagonist (ketamine) and agonist (nicotine). Therefore the mechanism of action is: NMDA receptor antagonist (ketamine) and nicotinic acetylcholine receptor agonist (nicotine).,Antagonist
29718385,The mechanism of action is a phosphodiesterase 9 inhibitor. The target of the chemical reaction is the enzyme phosphodiesterase 9. There are no receptor subtypes mentioned in the article.,Antagonist
22750079,The article does not provide information about the mechanism of action or receptor subtype of the drug being evaluated (mirtazapine).,Antagonist
11890187,The mechanism of action for mianserin is as a 5-HT2 antagonist. There is no mentioned drug being evaluated with a specific receptor subtype. The typical antipsychotic drugs are mentioned as D2 antagonists.,Antagonist
15721055,"The drug being evaluated in this study is metoclopramide, which is a dopamine antagonist. There is no specific information provided in the article about the receptor subtype(s) targeted by metoclopramide.",Antagonist
29397899,The mechanism of action is: D-amino acid oxidase inhibitor. The target of the chemical reaction is: D-amino acids. The receptor subtype(s) are not specifically mentioned in the article.,Antagonist
17570902,"The article does not discuss the evaluation of any specific drugs or their mechanism of action. However, it does mention atypical antipsychotics as a class of drugs that have the propensity to induce weight gain in normal-weight patients with schizophrenia.",Antagonist
2865252,"N/A, as the article is about maintenance therapy and antipsychotic medication in general rather than a specific drug or mechanism of action.",Antagonist
23375406,The mechanism of action is: 5-HT3 antagonism. The receptor subtype(s) is/are: 5-HT3. The drug being evaluated is: granisetron.,Antagonist
15677607,The receptor(s) targeted by ondansetron are: 5-HT3. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: 5-HT3 receptor antagonist.,Antagonist
19906345,"The mechanism of action is NMDA receptor antagonism. The drug being evaluated is memantine, which acts as a weak nonselective NMDA receptor antagonist. There is no information provided about specific NMDA receptor subtypes targeted by the drug.",Antagonist
10671405,The receptor(s) are: selective serotonin 3. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: selective serotonin 3 receptor antagonist.,Antagonist
351804,The mechanism of action is: opiate antagonist. The target of the chemical reaction is: endorphins. The receptor subtype(s) are not specified in the article. Therefore the mechanism of action is: opiate antagonist targeting endorphins.,Antagonist
29499855,The mechanism of action is: Glycine transporter-1 (GlyT1) inhibitor. The receptor subtype(s) are: GlyT1. The binding mode(s) are not specified.,Antagonist
24696094,The mechanism of action is glycine reuptake inhibition through blockade of the glycine transporter type 1. There is no specific receptor subtype mentioned in this article.,Antagonist
14634716,"The mechanism of action of naltrexone is a narcotic antagonist which targets the mu, delta, and kappa opioid receptors in the brain. It does not have a direct target on the symptoms of schizophrenia.",Antagonist
30101,The receptor(s) are: opiate. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: opiate receptor antagonist.,Antagonist
23899638,The article does not discuss the mechanism of action or receptor subtype(s) of any specific drug. It rather discusses the estimated dopamine D2 receptor occupancy levels needed for therapeutic efficacy in schizophrenia treatment.,Antagonist
335903,The mechanism of action and receptor subtype are not specified in the article as the drug naloxone hydrochloride is a narcotic antagonist and not acting on a specific receptor subtype.,Antagonist
31876117,The article does not provide information on the mechanism of action or receptor subtype of paliperidone palmitate.,Antagonist
29090685,"The drug being evaluated is tocilizumab, which is an interleukin-6 (IL-6) receptor antibody. It does not have a specific receptor subtype or binding mode, as it is designed to inhibit the activity of the IL-6 receptor.",Antagonist
19542525,The article does not specify the mechanism of action or receptor subtype(s) of either ziprasidone or olanzapine.,Antagonist
29193710,"The mechanism of action is anticholinergic, specifically targeting muscarinic receptors. The study evaluated the efficacy of scopolamine ointment against clozapine-induced hypersalivation in schizophrenia patients and healthy adults.",Antagonist
23099060,"The drug being evaluated is L-carnosine, which is an antioxidant and anti-glycation agent. The article does not mention any specific receptor subtype or mechanism of action for the drug. It is being evaluated as a treatment for cognitive dysfunction in schizophrenia, which may be related to glutamatergic dysfunction and inadequate antioxidant defenses at glutamatergic synapses.",Antagonist
6319107,"The mechanism of action is: opioid antagonist. The receptor(s) are: opioid receptors, but the subtype(s) are not specified.",Antagonist
22809972,The article does not provide information on the mechanism of action(s) or the receptor subtype(s) of the drugs being evaluated (paliperidone ER and risperidone). These drugs are both classified as antipsychotic agents and dopamine antagonists.,Antagonist
17242805,"The drugs being evaluated in this article are olanzapine and nizatidine. The mechanism of action of olanzapine is to block the dopamine and serotonin receptors in the brain, while the mechanism of action of nizatidine is as a histamine H2 receptor antagonist. There are no receptor subtypes mentioned for these drugs in the article.",Antagonist
14645311,"The article is about a comparison of two antipsychotic drugs, olanzapine and haloperidol, and does not mention specific mechanisms of action or receptor subtypes.",Antagonist
23158779,"There are no drugs being evaluated in this article; therefore, there is no mechanism of action or receptor subtype specified.",Antagonist
6138923,The mechanism of action for clonidine is to block noradrenergic neurotransmission. It is not evaluated with a specific receptor subtype or chemical reaction.,Antagonist
19552488,"The drug blonanserin is described as having potent dopamine D(2) and serotonin 5-HT(2) antagonist properties, but the article does not provide information about the receptor subtype(s) targeted by haloperidol. Therefore, it is not possible to answer this question fully.",Antagonist
17519641,"The article does not mention any drugs being evaluated with specific mechanism of action or receptor subtype. It only discusses the side effect of hyperprolactinemia associated with the use of risperidone, an atypical antipsychotic drug, in male schizophrenia patients.",Antagonist
23131879,There are no drugs or mechanisms of action discussed in this article. It is a study investigating the trajectory of AGRP levels during antipsychotic-induced weight gain in patients with schizophrenia.,Antagonist
30449883,The drug being evaluated is lumateperone (ITI-007) and the receptor subtype is the dopamine D2 receptor. The article does not provide information on the mechanism of action/target of the chemical reaction of lumateperone.,Antagonist
8868206,The mechanism of action is: narcotic antagonist. The receptor subtype(s) are not specified in the article.,Antagonist
6266259,The mechanism of action is: opiate receptor antagonist. The receptor subtype(s) are: central opiate receptors.,Antagonist
11001233,"Olanzapine has higher affinity for serotonin 5-HT2 receptors than for dopamine-2 receptors. Sulpiride is a selective D2 blocker. The combination/ augmentation of olanzapine and sulpiride enhances D2 blockage and is suggested as an efficient strategy for treating patients with treatment-resistant schizophrenia. Therefore, the mechanism of action involves the serotonin and dopamine receptors.",Antagonist
9474443,"The drug being evaluated is 123I-iomazenil, which is a selective benzodiazepine antagonist used as a radioligand. The mechanism of action is binding to the GABAA/benzodiazepine receptor. The subtype(s) of the receptor are not specified in this article.",Antagonist
30738698,"The article does not provide information about the mechanism of action(s) or the receptor subtype(s) of any specific drug(s). The article instead focuses on the impact of anticholinergic medication burden on cognitive function in patients with treatment refractory schizophrenia, and how targeted cognitive training may help mitigate these effects.",Antagonist
28839342,"The mechanism of action is: vesicular monoamine transporter 2 (VMAT2) inhibitor. The target is the VMAT2 protein responsible for packaging and regulating the release of monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine. There are no specific receptor subtypes targeted by Valbenazine.",Antagonist
16679001,The mechanism of action is blocking dopamine D2 receptors. The receptor subtype is dopamine D2. The drug being evaluated is haloperidol.,Antagonist
15840416,There are no drugs being evaluated in this article. The article describes the effects of neuroleptic medications on levels of certain proteins in the blood of schizophrenic patients. The proteins of interest are the soluble IL-2 receptor-alpha and IL-1 receptor antagonist. There is no mention of target receptors or mechanism of action of any drugs.,Antagonist
8122957,"The mechanism of action is: noncompetitive antagonist of the N-methyl-D-aspartate subtype of excitatory amino acid receptor. The receptor subtype is: N-methyl-D-aspartate (NMDA) subtype of excitatory amino acid receptor. Therefore, the drug being evaluated is a noncompetitive NMDA antagonist, ketamine.",Antagonist
9325559,"The receptor(s) are: N-methyl-D-aspartate (NMDA). The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: NMDA receptor antagonist. Additionally, clozapine is an atypical antipsychotic agent with complex mechanisms of action.",Antagonist
28839341,The drug being evaluated is valbenazine (NBI-98854). The article does not provide information on the mechanism of action or receptor subtype targeted by valbenazine.,Antagonist
10319907,"The drug being evaluated is cyproheptadine, which is a serotonin-blocking agent. The article mentions growing interest in investigating the role of 5-HT receptors in the pathophysiology of schizophrenia, but it does not specify if cyproheptadine targets any specific receptor subtype. Therefore, the mechanism of action is a serotonin-blocking agent.",Antagonist
7846205,"The drug being evaluated is ritanserin, which is a selective serotonin-2 antagonist. It is not evaluated with any specific receptor subtype, but its mechanism of action is to block serotonin-2 receptors. The study ruled out any direct D2-dopamine blockade activity.",Antagonist
3662745,The mechanism of action is: alpha 2-adrenergic receptor antagonist. The receptor subtype(s) are: alpha 2-adrenergic. Therefore the drug being evaluated here is: yohimbine.,Antagonist
860138,"The mechanism of action of naloxone is as a specific narcotic antagonist, which targets the opioid receptor subtypes. However, the article does not provide information on which specific receptor subtypes are being targeted in the study.",Antagonist
7831446,"The mechanism of action of cimetidine is H2 antagonist, and the receptor subtype targeted is the H2 receptor. The mechanism of action of clozapine is a dopamine, 5-HT2/5-HT1C, and histamine antagonist. The receptor subtypes targeted are dopamine, 5-HT2, and H1 receptors.",Antagonist
12478881,The mechanism of action is: antiglucocorticoid. The target of the chemical reaction is: cortisol. The receptor subtype(s) are not mentioned in the article. The drug being evaluated is ketoconazole.,Antagonist
568293,"The drug being evaluated is N-acetyl-p-amino-phenol (paracetamol, acetaminophen). Its mechanism of action is the suppression of prostaglandin E, and it does not involve a receptor subtype.",Antagonist
12721815,"The article does not provide information on the mechanism of action or receptor subtype for the drugs being evaluated (olanzapine, risperidone, and haloperidol).",Antagonist
9197911,There is no specific drug being evaluated with a mechanism of action or receptor subtype mentioned in this article.,Antagonist
19242406,"The drug is memantine, which is an NMDA antagonist. The target of the chemical reaction is the NMDA receptor, which is involved in regulating PPI (prepulse inhibition). The receptor subtype(s) are not specified in the article. Therefore the mechanism of action is NMDA receptor antagonist.",Antagonist
16870959,"There is no specific drug being evaluated in this article, so there is no mechanism of action or receptor subtype information.",Antagonist
12827347,"The article mentions three different drugs: olanzapine, risperidone, and haloperidol. However, the article does not directly state the mechanism of action and receptor subtype for each drug. The article does suggest that haloperidol and risperidone have a greater activity in the dorsal striatum, which may induce extrapyramidal motor symptoms and impair procedural learning that depends on this region. In contrast, olanzapine is pharmacologically similar to clozapine and has a low incidence of EPS induction. The article suggests that olanzapine may not have a deleterious effect on procedural learning in comparison to haloperidol and risperidone.",Antagonist
9260735,The mechanism of action for nifedipine is: calcium channel antagonist. There is no specific receptor subtype mentioned in the given abstract.,Antagonist
28674870,The mechanism of action is alpha2-adrenergic receptor antagonism by antipsychotics. The receptor subtype(s) are alpha2-adrenergic receptors.,Antagonist
14751424,"The article does not specify the mechanism of action or receptor subtype(s) of the drugs (risperidone and haloperidol) being evaluated, as it focuses on their efficacy and adverse effects in the treatment of schizophrenia.",Antagonist
16123767,"The mechanism of action and receptor subtype(s) are not explicitly stated in the article. However, it is mentioned that ketamine is an excitatory amino acid antagonist. Its main mechanism of action is thought to be blocking the NMDA receptor, a subtype of glutamate receptor.",Antagonist
25864950,"There are no specific drugs being evaluated in this study, rather the study is examining the optimal threshold for dopamine D₂ receptor blockade in the maintenance treatment of schizophrenia. No mechanism of action or receptor subtype is mentioned.",Antagonist
17374,"The drug being evaluated is metyrosine, which inhibits tyrosine hydroxylase, the rate-limiting enzymatic step in dopamine synthesis. Therefore, the mechanism of action is dopamine synthesis inhibitor. There is no receptor subtype targeted in this study.",Antagonist
20727411,"The drug being evaluated is S-ketamine, a non-competitive NMDA receptor antagonist. The mechanism of action is blocking the NMDA receptor, which leads to psychopathological symptoms similar to those observed in schizophrenia. The receptor subtype is the NMDA receptor.",Antagonist
8726548,"The article does not mention any specific drug or mechanism of action being evaluated. The study focused on the use of smooth pursuit eye movements (SPEM) as an outcome measure in an open-label clinical trial of famotidine as an adjunctive medication for schizophrenia treatment. Famotidine is an H-2 antagonist that has been proposed for the treatment of negative symptoms in schizophrenia, but the article does not provide information on its specific mechanism of action or receptor subtype.",Antagonist
27789188,The mechanism of action is an inhibitor of glycine transporter type-1 (GlyT1). There are no specific receptor subtypes mentioned.,Antagonist
9519099,"The drug(s) being evaluated are clozapine and sulpiride. The mechanism of action for clozapine is as a weak D2-dopaminergic antagonist, while the mechanism of action for sulpiride is as a selective D2 blocker. The receptor subtype(s) being targeted are the D2 dopaminergic receptors. Together, the combination is hypothesized to enhance the efficacy of clozapine by enhancing D2 blockade.",Antagonist
20737516,The article does not provide information about the mechanism of action or receptor subtype of mirtazapine.,Antagonist
16171976,"The article does not mention any drugs being evaluated, thus there is no mechanism of action or receptor subtype described.",Antagonist
8923336,"The drug being evaluated is ketamine, which is an NMDA receptor antagonist. The receptor subtype is the NMDA receptor. The mechanism of action is the blocking of the NMDA receptor, which has been shown to impair learning and memory in animal models. However, in this study, ketamine did not have any effects on memory or other cognitive functions in schizophrenia patients.",Antagonist
18255098,The mechanism of action is: glucocorticoid receptor antagonist. The target of the chemical reaction is: the hypothalamic-pituitary-adrenal (HPA) axis. There is no information provided on receptor subtypes. The drug being evaluated is mifepristone.,Antagonist
15893916,The article does not mention any drugs or mechanisms of action. It is a study investigating learning and memory deficits in schizophrenia patients.,Antagonist
20732371,There are no drugs being evaluated in this article. The study investigated the role of polymorphisms in the CCK gene and its receptors in antipsychotic-induced weight gain in schizophrenia patients.,Antagonist
19831836,"The article does not provide information about the specific mechanism of action or receptor subtype of Risperidone long-acting injectable (RLAI). However, RLAI is described as an atypical antipsychotic agent intended for long-term management of schizophrenia.",Antagonist
7078714,The mechanism of action of diazepam is to enhance the effect of gamma-aminobutyric acid (GABA) and bind to the benzodiazepine receptor. The receptor subtype(s) that the drug is being evaluated with is the benzodiazepine receptor.,Antagonist
15099605,"The article does not specify the mechanism of action or receptor subtype of the antipsychotic drugs haloperidol and risperidone, or the anticholinergic drug benztropine.",Antagonist
15869707,The article does not provide information on the mechanism of action or receptor subtype of amisulpride.,Antagonist
22094124,The drug is biperiden and the receptor subtype is the muscarinic M1 receptor. The mechanism of action is a muscarinic M1 antagonist.,Antagonist
23609382,"The mechanism of action for memantine is that it is an NMDA receptor antagonist, which reduces glutamate excitotoxicity in the brain. Risperidone is an atypical antipsychotic that blocks dopamine and serotonin receptors. Therefore, the drug being evaluated in this study is memantine, which is an NMDA receptor antagonist. The receptor subtype(s) being targeted are the NMDA receptors.",Antagonist
36874957,The article does not provide information about the mechanism of action or receptor subtype(s) of betahistine.,Antagonist
24525661,The drug being evaluated is Org 25935 and its mechanism of action is a selective inhibitor of type 1 glycine transporter. There are no receptor subtypes mentioned.,Antagonist
7612873,The mechanism of action of ketamine is being evaluated as a non-competitive antagonist of the NMDA receptor. The article does not mention receptor subtypes.,Antagonist
9347382,"The mechanism of action is anticholinergic, and the drug evaluated is trihexyphenidyl, a muscarinic antagonist. The target receptor subtype(s) is muscarinic acetylcholine receptors.",Antagonist
8829717,The mechanism of action for cyproheptadine is antiserotonergic. There is no information about receptor subtype(s) in the article.,Antagonist
19011427,"The article does not provide information about the specific mechanism of action or receptor subtype for olanzapine or aripiprazole, but they are both classified as antipsychotic agents and dopamine antagonists.",Antagonist
30357437,"The drug being evaluated is ketamine, which is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. The receptor subtype is NMDA. Therefore, the mechanism of action is NMDA receptor blockade.",Antagonist
15101567,The article does not mention any specific drug being evaluated with a target or receptor subtype. The study was focused on the effects of discontinuing anticholinergic medication on cognitive function in elderly schizophrenia patients.,Antagonist
10448449,The receptor(s) is/are: 5-HT2. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: 5-HT2 receptor antagonist.,Antagonist
30614850,The mechanism of action is muscarinic antagonist and the target receptor subtype is not specified in the article. The drug being evaluated is hyoscine (scopolamine).,Antagonist
11552770,The mechanism of action of reboxetine is as a noradrenergic reuptake inhibitor. There is no mention of specific receptor subtypes being evaluated in this study.,Antagonist
10094133,The article does not mention any drugs or mechanisms of action. It is a study investigating the association between a silent mutation polymorphism of the 5HT2A gene and schizophrenia or clozapine response in a Chinese population.,Antagonist
14618553,"The article does not specify the mechanism of action(s) or the receptor subtype(s) for olanzapine and haloperidol, but they are both antipsychotic agents.",Antagonist
17397098,There is no specific drug or mechanism of action being evaluated in this article. The article is focused on examining the frequency and socio-demographic and clinical correlates of anticholinergic medication (ACM) prescription in Chinese patients with schizophrenia.,Antagonist
22189657,The mechanism of action is noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonism. The receptor subtype(s) are NMDA receptors. The drug being evaluated is S-ketamine.,Antagonist
32004636,The article does not provide information on the mechanism of action or receptor subtype(s) for the drugs being evaluated (olanzapine and samidorphan).,Antagonist
31185023,The drug being evaluated is the histone methyltransferase inhibitor BIX-01294. It targets histone modifications and gene expression in both clinical and mouse models. The mechanism of action is inhibition of HMTs. There are no receptor subtypes mentioned in this article.,Antagonist
2484825,The mechanism of action is a dopamine and serotonin receptor antagonist. The receptor subtype for dopamine is D2 and for serotonin is 5-HT2.,Antagonist
9778666,The article does not mention any drugs being evaluated. It discusses the genetic influence of the APOE epsilon 4 allele on the psychotomimetic response to ketamine in schizophrenics.,Antagonist
17293085,"The drug being evaluated is mecamylamine, which is a nicotinic acetylcholine receptor antagonist. The receptor subtype targeted is not specified in the given abstract.",Antagonist
17360162,The article does not mention any drugs being evaluated with specific mechanism of actions or receptor subtypes. It is a study on the effects of typical and atypical antipsychotic drugs on basal ganglia volumes in drug-naive first-episode schizophrenia patients.,Antagonist
6145176,The mechanism of action is alpha 1-noradrenergic receptor antagonism. The target of the chemical reaction is the alpha 1-adrenergic receptor subtype. The drug being evaluated is prazosin.,Antagonist
17049818,The article does not provide information on the mechanism of action or receptor subtype of long-acting injectable risperidone.,Antagonist
8584611,The mechanism of action is selective D1 dopamine receptor antagonism. The receptor subtype is the D1 dopamine receptor.,Antagonist
8828997,The mechanism of action of famotidine is as an H2 (histamine) receptor antagonist. The receptor subtype is the H2 receptor.,Antagonist
9825168,The article does not mention any specific mechanism of action or receptor subtype for clozapine.,Antagonist
9829650,"The drug being evaluated is haloperidol, which is a typical antipsychotic that works by blocking dopamine receptors (specifically D2 receptors). The mechanism of action is therefore dopamine antagonist. There is no mention of receptor subtypes in this article.",Antagonist
17076934,The mechanism of action is: dopamine D2/D3 receptor antagonist. The receptor subtype(s) are: D2 and D3 receptors. The drug being evaluated is tiapride.,Antagonist
15560968,"The drug being evaluated in this study is ketamine, which is an antagonist of the NMDA receptor. The receptor subtype is the NMDA receptor. Therefore, the mechanism of action is NMDA receptor antagonist.",Antagonist
16165104,The article does not mention the mechanism of action or receptor subtype of the drugs being evaluated (Hypericum extract and S-ketamine).,Antagonist
31234240,"The article does not mention any specific mechanism of action or receptor subtype. However, it does mention that valbenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia.",Antagonist
1485530,None,Antagonist
16194258,The article does not specifically mention the mechanism of action or receptor subtype of risperidone. It only evaluates the clinical efficacy and method of switching medication for patients with schizophrenia.,Antagonist
7751433,"The drug being evaluated in this study is alosetron, which is a 5-HT3 receptor antagonist. The target receptor subtype is the 5-HT3 receptor. The study investigated the effect of alosetron on the pharmacokinetics of haloperidol in schizophrenic patients. Haloperidol is a typical antipsychotic medication that is not a direct target of alosetron.",Antagonist
15710053,"The drug being evaluated is long-acting injectable risperidone, which is an antipsychotic agent that is a dopamine antagonist. The receptor subtype being targeted is the dopamine D2 receptor.",Antagonist
19192440,"The mechanism of action is not explicitly stated in the article for flunarizine, but it is described as a nonspecific calcium channel blocker and a dopamine D2 receptor blocker. Haloperidol is a dopamine antagonist. The receptor subtype(s) for flunarizine are not specified.",Antagonist
12920408,The article is not about evaluating drugs with a specific mechanism of action or receptor subtype. It is about exploring the relationship between serum antimuscarinic activity and clozapine treatment in patients with schizophrenia.,Antagonist
15163444,"The drug being evaluated in this study is famotidine, which is an H2 antagonist. The mechanism of action of famotidine is to block the H2 receptors, which reduces the amount of acid produced by the stomach. There is no information given in the article about the receptor subtypes.",Antagonist
12413642,"The article mentions beta-adrenergic antagonists, but does not specify the subtype or the mechanism of action beyond blocking the adrenergic beta receptors. The focus of the article is on the effects of clozapine treatment and concurrent beta-adrenergic antagonist treatment on glucose and lipid measures.",Antagonist
9090331,"The article does not provide information on the mechanism of action or receptor subtype(s) of olanzapine or haloperidol. However, it does state that olanzapine is an atypical antipsychotic and haloperidol is a conventional dopamine D2 antagonist.",Antagonist
28232170,The mechanism of action is N-methyl-D-aspartate receptor (NMDAR) antagonism. The receptor subtype(s) involved is/are the NMDAR. Therefore the mechanism of action is NMDAR antagonist.,Antagonist
10839333,"The drug being evaluated is quetiapine, and its mechanism of action is as an atypical antipsychotic. The receptor subtype being studied is the dopamine type 2 (D2) receptor.",Antagonist
8584613,The mechanism of action is: D1 antagonist. The receptor subtype is: dopamine D1 receptor. The drug being evaluated is SCH 39166.,Antagonist
25529756,"The mechanism of action of the drug, ranitidine, is as an H2 blocker, which is a type of histamine receptor antagonist. It does not directly interact with any specific receptor subtype.",Antagonist
17077809,"The drugs being evaluated are antipsychotic agents, specifically risperidone and olanzapine. Their mechanism of action is blocking of dopamine D2 receptors. The receptor subtype is dopamine D2.",Antagonist
12111340,None,Antagonist
9448657,The article does not mention the mechanism of action or the receptor subtype of the drugs being evaluated (risperidone and haloperidol).,Antagonist
9377587,The receptor(s) are: histamine-2 (H2). The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: histamine-2 (H2) antagonist.,Antagonist
9347380,"The mechanism of action of the drugs (mianserin and trazodone) in the study is not clearly mentioned in the given abstract. However, it is mentioned that both these drugs have serotonin 2 antagonist properties and are used as serotonergic antidepressants.",Antagonist
10739409,"The drug being evaluated in this study is haloperidol, which is an antipsychotic agent that blocks dopamine D(2) receptors. Therefore, the mechanism of action is dopamine D(2) receptor antagonist. The study also used the radioligand [(11)C]raclopride to measure D(2) receptor occupancy with positron emission tomography.",Antagonist
19794330,"The article does not discuss the evaluation of drugs with a specific mechanism of action or receptor subtype. Instead, it discusses the role of genetic variants in the subunit genes HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E on treatment response to antipsychotics in schizophrenia.",Antagonist
27028980,The mechanism of action of metoclopramide is as a dopamine D2 receptor antagonist. There is no mention of receptor subtypes in this particular article.,Antagonist
1103205,"The article does not mention the specific mechanism of action or receptor subtype for haloperidol, chlorpromazine, or benztropine. However, it suggests that chlorpromazine has inherent anticholinergic properties that may contribute to its lower potency compared to haloperidol. Benztropine is a parasympatholytic drug that can diminish the therapeutic response to both neuroleptics.",Antagonist
1362205,The mechanism of action and receptor subtype are not specified in the article as the focus is on the clinical trial and not the specific pharmacology of proglumide.,Antagonist
14599005,"The article does not provide information on drugs or their mechanisms of action. It focuses on the use of mixed-effects models and region-of-interest analyses in longitudinal fMRI studies of drug effects on human memory function in the hippocampus, a key region affected by brain disorders like Alzheimer's disease and schizophrenia.",Antagonist
11022399,None,Antagonist
12177587,The article does not provide information on the mechanism of action or receptor subtypes of the drugs being evaluated (amisulpride and flupentixol).,Antagonist
22442101,The article does not provide information about specific drugs and their mechanism of action or receptor subtype. It focuses on comparing the extrapyramidal motor side effects of first- and second-generation antipsychotic drugs.,Antagonist
9611669,"The mechanism of action and receptor subtype(s) for olanzapine and haloperidol are not specified in the article. However, olanzapine is classified as an atypical antipsychotic and is known to target multiple neurotransmitter systems including dopamine, serotonin, and histamine. Haloperidol is a conventional antipsychotic and acts primarily as a dopamine antagonist.",Antagonist
9497016,"The drug being evaluated is quetiapine (Seroquel), which acts as an antagonist for both dopamine D2 receptors and serotonin 5HT2 receptors. There are no specific receptor subtypes mentioned in the abstract.",Antagonist
22814006,"The article does not specifically mention any mechanism of action or receptor subtype for the antipsychotic drugs (perazine, olanzapine, and ziprasidone). However, it does mention that therapeutic effects of all clinically used antipsychotics are related to the reduction of dopaminergic transmission in the limbic system. This suggests that the drugs may act on dopamine receptors. The article also mentions several dopaminergic genes (DRD2, DRD2/ANKK1, DAT1, COMT, and MAOA) that were genotyped, which suggests that their corresponding proteins may play a role in response to antipsychotic drugs. However, the article does not provide specific information on the mechanisms of these genes/proteins.",Antagonist
24326395,"The drug(s) being evaluated are: ketamine and risperidone. The mechanism of action and receptor subtype being targeted are: 
- ketamine: non-competitive N-methyl-D-aspartate receptor antagonist
- risperidone: atypical antipsychotic, target receptors include dopamine and serotonin receptors",Antagonist
30136756,The mechanism of action is inhibition of glycine transporter 1 (GlyT1). There is no information provided about receptor subtypes being evaluated with this drug.,Antagonist
23417515,"The drug being studied is ziprasidone, which is an atypical antipsychotic. The mechanism of action is not specified in this abstract, but it is known to work by antagonizing dopamine D2/3 receptors in the brain.",Antagonist
22906553,"The drugs evaluated in the study are not explicitly mentioned in the abstract. However, the study used the high affinity ligand [(18)F]-fallypride (FP) to measure dopamine D(2/3) receptor availability throughout the brain. Ketamine, an N-methyl-D-aspartate antagonist, was used to induce psychotic symptoms. Therefore, the mechanism of action is: N-methyl-D-aspartate antagonist (ketamine) and dopamine D(2/3) receptor availability measurement (FP). The subtype(s) of the dopamine D(2/3) receptors are not specified.",Antagonist
15643094,"The article is not evaluating drugs but instead is exploring the influence of the Ser9Gly polymorphism on response to risperidone in schizophrenia patients. The drug being evaluated is risperidone, which is a dopamine D3 antagonist.",Antagonist
23370794,"The drugs being evaluated in this study are lamotrigine and risperidone, both of which are hypothesized to reduce ketamine-induced glutamate release. The article does not mention any specific receptor subtypes for these drugs. Ketamine acts as an N-methyl-D-aspartate receptor antagonist. The article also mentions the use of glutamatergic agents, but does not provide details on which specific agents were used or their mechanism of action.",Antagonist
33961287,The receptor(s) are: dopamine D2 and serotonin 5-HT7. The subtype(s) are: N/A. The binding mode(s) are: antagonist (for 5-HT7) and antagonist/medication (for D2). Therefore the mechanism of action is: dopamine D2 and serotonin 5-HT7 receptor antagonist/medication.,Antagonist
23809226,"The drug being evaluated is Quetiapine XR. The mechanism of action is not specified in the abstract, but the drug and its metabolite have moderate to high affinity for dopamine D2 and serotonin 5-HT2A receptors, and the metabolite alone has high affinity for the norepinephrine transporter (NET). Therefore, the drug is likely acting as an antagonist or inverse agonist at the dopamine and serotonin receptors and as an inhibitor at the norepinephrine transporter.",Antagonist
23591780,The article does not provide information on the mechanism of action or receptor subtype of bitopertin. It only discusses the use of physiologically based pharmacokinetic (PBPK) modelling to predict its clinical pharmacokinetics.,Antagonist
3737785,The mechanism of action is: cholecystokinin receptor antagonist. The subtype(s) are: not specified. The drug being tested is proglumide.,Antagonist
21890590,The mechanism of action for sertindole is mixed D(2)/5-HT(2) receptor antagonism. There is no specific receptor subtype mentioned for P50 suppression or PPI.,Antagonist
9169965,"The article does not provide information about the mechanism of action or receptor subtype of the drugs. It only mentions the names of the drugs and their doses: risperidone (2, 6, 10, or 16 mg/day) and haloperidol (20 mg/day).",Antagonist
25102328,"The mechanism of action is opioid antagonism, with the drug being evaluated being naltrexone (NTX) 25 mg/d. The target of the chemical reaction is the endogenous opioid system. There are no receptor subtypes mentioned in the abstract.",Antagonist
21121175,The mechanism of action is: N-methyl-D-aspartate antagonist. The target of the chemical reaction is: the N-methyl-D-aspartate receptor. The subtype(s) are: not specified. Therefore the mechanism of action is: N-methyl-D-aspartate receptor antagonist.,Antagonist
12680744,"The mechanism of action of procyclidine is an anticholinergic drug. The target of the chemical reaction is the muscarinic acetylcholine receptor subtype, specifically M1 and M2 receptors.",Antagonist
9272481,The drug is: ketamine. The receptor(s) are: N-Methyl-D-Aspartate (NMDA). The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: NMDA receptor antagonist.,Antagonist
28839340,The mechanism of action is: vesicular monoamine transporter 2 (VMAT2) inhibitor. There is no information about specific receptor subtypes being evaluated in this article.,Antagonist
12681371,"The mechanism of action is N-methyl-D-aspartate (NMDA) receptor antagonist, as the drug being evaluated is ketamine. The receptor subtype(s) are NMDA receptors.",Antagonist
11343683,The mechanism of action is noncompetitive N-methyl-D-aspartate antagonist. The receptor subtype(s) are: N-methyl-D-aspartate receptors.,Antagonist
15811593,The mechanism of action for Ondansetron is as a selective serotonin 3 receptor (5-HT(3)) antagonist. The target of the chemical reaction is the 5-HT(3) receptor subtype of the serotonin receptor.,Antagonist
26223493,"The mechanism of action and receptor subtype(s) for each drug are as follows:
- Ketamine: NMDA receptor antagonist
- Risperidone: dopamine antagonist
- Lamotrigine: sodium channel blocker

There is no information provided about the specific receptor subtype(s) for each drug.",Antagonist
17591659,The mechanism of action of the drug is an N-methyl-D-aspartate (NMDA) receptor antagonist. The article does not mention any specific receptor subtype being evaluated.,Antagonist
30888624,"The article does not describe the mechanism of action or receptor subtype for olanzapine or samidorphan. However, it states that olanzapine is metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT)1A4 and cytochrome P450 (CYP)-mediated oxidation, mainly by CYP1A2, while samidorphan is metabolized predominantly by CYP3A4. The study evaluated the effects of CYP3A4 induction on the pharmacokinetics of OLZ/SAM.",Antagonist
19968833,"The mechanism of action is: dopamine agonist. The receptor subtype is: Dopamine D2 receptor. Therefore the drug being evaluated, bromocriptine, acts as a dopamine D2 receptor agonist.",Antagonist
4560057,The mechanism of action is to increase brain serotonin levels by administering the serotonin precursor L-5-hydroxytryptophan with a peripheral decarboxylase inhibitor. There is no specific receptor subtype targeted by the drug.,Antagonist
15048609,"The receptor(s) are: muscarinic. The subtype(s) are: M4. The binding mode is: antagonist. Therefore, the mechanism of action is: muscarinic M4 receptor antagonist.",Antagonist
10962221,The article is discussing the effectiveness of adjunctive imipramine in treating post-psychotic depression in schizophrenia patients. There is no mention of specific mechanism of action or receptor subtypes being evaluated.,Antagonist
25987642,"The drug being evaluated is ketamine, which is an NMDA receptor antagonist. The target of the chemical reaction is the NMDA receptor.",Antagonist
29453445,"The drug being evaluated in this study is ketamine, which is an antagonist of the N-methyl-D-aspartate receptor (NMDAR). Therefore, the target of the chemical reaction is the NMDAR. No specific receptor subtype is mentioned in the abstract.",Antagonist
10928313,The receptor(s) are: 5HT(2A) serotonin. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: 5HT(2A) serotonin receptor antagonist.,Antagonist
29141124,The mechanism of action of valbenazine is as a highly selective vesicular monoamine transporter 2 inhibitor. It is not being evaluated with any receptor subtype.,Antagonist
22591910,"The article does not mention any specific drugs being evaluated with receptor subtypes or mechanisms of action. Instead, it discusses the use of imaging techniques to investigate changes in the dopamine system in patients with Ultra High Risk for psychosis.",Antagonist
16139819,"The drugs being evaluated are amisulpride and olanzapine. The article mentions that amisulpride is a combined 5-HT2A/D2 antagonist and that olanzapine is a pure D2/D3 antagonist. Therefore, the mechanism of action for amisulpride is 5-HT2A/D2 receptor blockade, while the mechanism of action for olanzapine is D2/D3 receptor blockade. No specific receptor subtypes were mentioned for the startle response and habituation mechanisms being studied.",Antagonist
15889942,The mechanism of action of amisulpride is a selective D(2)-D(3) antagonist. There is no mention of receptor subtypes being evaluated.,Antagonist
1352050,The mechanism of action is: selective dopamine (D2)-receptor antagonist. The receptor subtype is: dopamine D2 receptor. The drug being evaluated is remoxipride.,Antagonist
19758522,"The mechanism of action is: anticholinergic. The receptor subtype(s) are: N/A. The drug(s) being evaluated are: ipratropium bromide. Therefore, the mechanism of action is: anticholinergic agent.",Antagonist
27076209,"The drug being evaluated is memantine, which is an NMDA antagonist. The receptor subtype(s) being targeted are the ionotropic NMDA receptors, specifically the GRIN3A gene.",Antagonist
11557159,"The mechanism of action of ketamine is as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, although this information is not directly stated in the abstract.",Antagonist
25693889,The receptor(s) are: NMDA/glutamate. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: NMDA/glutamate receptor antagonist (S+ -ketamine).,Antagonist
19648218,The mechanism of action is: selective inhibitor of the glycine transporter 1. The receptor subtype(s) are: glycine plasma membrane transport proteins and N-methyl-D-aspartate receptors.,Antagonist
15257068,The article does not specifically mention a drug being evaluated with a receptor subtype or mechanism of action. It discusses the effect of sertraline on the plasma concentrations of risperidone and its active metabolite in patients with schizophrenia or schizoaffective disorder.,Antagonist
27378314,"The mechanism of action is: selective phosphodiesterase 9A inhibitor. The target(s) of the chemical reaction are: 3',5'-Cyclic-AMP Phosphodiesterases. No receptor subtype(s) are mentioned in the article.",Antagonist
9894580,"The drugs being evaluated are amisulpride and flupenthixol, which are neuroleptics with different receptor affinity profiles. Amisulpride is a selective D2-like dopamine antagonist, and flupenthixol is a mixed D1/D2-like antagonist that also blocks serotonin, H1, and D1 receptors. They affect anterior pituitary hormone secretion in schizophrenia patients by elevating prolactin plasma levels and increasing basal TSH secretion. The specific receptor subtype(s) are not mentioned in the article.",Antagonist
27871302,"The drug(s) evaluated in this study are: glycopyrronium bromide (glycopyrrolate) and hyoscine hydrobromide (hyoscine), which are both muscarinic antagonists. The target of their chemical reaction is the muscarinic acetylcholine receptor subtype M1-M5.",Antagonist
20142308,The drug is a glycine reuptake inhibitor and the target is the glycine transporter subtype 1. There is no information provided on receptor subtype(s).,Antagonist
6346348,The mechanism of action of naloxone is as an opiate antagonist. The target receptor subtype is the mu-opioid receptor.,Antagonist
10565803,"The drug being evaluated is granisetron, which is a selective 5-HT3 receptor antagonist. The mechanism of action is blocking the activity of the 5-HT3 receptor subtype.",Antagonist
22706414,"The drug being evaluated is dimebon, which is a 5-HT6 antagonist. The target of the chemical reaction is the 5-HT6 receptor subtype.",Antagonist
17414239,"The drugs being evaluated are disulfiram and naltrexone. The mechanism of action of disulfiram is as an alcohol deterrent, while naltrexone is a narcotic antagonist. There is no mention of receptor subtype(s) in this article.",Antagonist
2564208,"The mechanism of action is beta-blocking. The receptor subtype is beta-2. Therefore, the drug is a beta-2 receptor antagonist.",Antagonist
3545130,The mechanism of action is: calcium channel antagonist. The receptor subtype(s) are not specified in the article.,Antagonist
8329149,The mechanism of action is a selective dopamine (D2)-receptor antagonist. The receptor subtype is D2.,Antagonist
29158012,The mechanism of action of the drugs is not mentioned in the abstract.,Antagonist
24218048,"The drug being evaluated is naltrexone, which is an opioid receptor antagonist. The targets of the chemical reaction are the opioid receptors. The subtype(s) of the opioid receptor are not specified in the abstract.",Antagonist
19436994,The article does not mention the mechanism of action or receptor subtype being evaluated with ketamine.,Antagonist
23817989,"There are no drugs being evaluated in this study, so there is no mechanism of action or receptor subtype mentioned.",Antagonist
21678422,The article does not describe any drugs being evaluated with a mechanism of action or receptor subtype. It describes a pharmacokinetic analysis of plasma curves obtained after the injection of a PET radioligand for D2-receptor raclopride during brain PET scans.,Antagonist
11292000,"The drug being evaluated is risperidone, which is an antipsychotic medication. The target of its action is the dopamine D2 receptor in the limbic-cortical regions of the brain. The subtype(s) of the receptor are not specified in the abstract. The mechanism of action is antagonist of the dopamine D2 receptor.",Antagonist
12630982,This article does not discuss any drugs or their mechanism of action.,Antagonist
12399142,"The drug(s) evaluated in this study are ketamine and haloperidol. The mechanism of action of ketamine is as an antagonist of the NMDA receptor. The mechanism of action of haloperidol is as an antipsychotic that blocks dopamine D2 receptors. The article suggests that disrupted P50 suppression and PPI found in schizophrenia may be related to reduced dopaminergic activity, most likely in the prefrontal cortex.",Antagonist
9306300,"The drugs being evaluated are dopamine receptor antagonists, specifically haloperidol and fluphenazine. The mechanism of action is blocking dopamine D2 receptors. No specific receptor subtypes are mentioned.",Antagonist
12650950,The mechanism of action of nizatidine is as a histamine H-2 receptor antagonist. There is no mention of any specific receptor subtype.,Antagonist
15517847,"The article discusses ziprasidone, an atypical antipsychotic drug that is available in both intramuscular and oral formulations. It does not mention the specific receptor subtypes or mechanism of action of the drug.",Antagonist
8703299,The receptor(s) are: N-methyl-D-aspartate (NMDA) receptors. The subtype(s) are: N/A. The binding mode is: noncompetitive antagonist. Therefore the mechanism of action is: NMDA receptor antagonist.,Antagonist
11105938,The mechanism of action is NMDA receptor antagonist and the receptor subtype is N-methyl-d-aspartate (NMDA) receptor.,Antagonist
10699226,The article does not provide information on the drugs' mechanism of action or receptor subtype being evaluated.,Antagonist
12923823,"The drug being evaluated is nizatidine, which is a histamine H2 antagonist. Its mechanism of action is to inhibit stomach acid production by blocking the H2 receptors on the cells that produce acid. There is no specific receptor subtype mentioned in this article.",Antagonist
15897673,"The mechanism of action is noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonism, and the drug being evaluated is the S-enantiomer of ketamine. The receptor subtype(s) are the NMDA receptors.",Antagonist
9626923,"There are no specific drugs being evaluated in this study, but clozapine is the antipsychotic medication being studied in relation to the CYP3A4 inhibitor itraconazole. The mechanism of action of itraconazole is inhibition of CYP3A4 enzyme. There are no receptor subtypes mentioned in this article.",Antagonist
9331521,"The mechanism of action is not explicitly stated in the abstract, but it is stated that clozapine has potent serotonergic antagonistic properties. Therefore, the target of the chemical reaction would be the serotonin receptor subtype(s), but the specific subtype(s) is/are not specified.",Antagonist
8935814,"The drugs being evaluated in this study are clozapine, a typical neuroleptic, and cyproheptadine, a non-selective serotonin receptor antagonist. The mechanism of action for clozapine is thought to involve a combination of dopamine receptor blockade and serotonin receptor blockade. The mechanism of action for neuroleptics is generally dopamine receptor blockade. The mechanism of action for cyproheptadine is serotonin receptor antagonist. The receptor subtype(s) targeted by these drugs are not specified in the abstract.",Antagonist
8104200,The receptor(s) are: alpha 2-adrenergic. The subtype(s) are: selective. The binding mode is: antagonist. Therefore the mechanism of action is: alpha 2-adrenergic antagonist.,Antagonist
16401158,"There is no mention of specific medications or mechanisms of action in this article. Instead, it compares two widely prescribed second-generation antipsychotics (risperidone and olanzapine) in terms of their efficacy in treating acutely ill psychotic patients based on duration of hospitalization.",Antagonist
8447237,The mechanism of action is predominantly a DA2 receptor antagonist. Therefore the receptor subtype is DA2.,Antagonist
15729082,The mechanism of action for risperidone is antagonism of dopamine receptors in the brain. There is no mention of evaluation with a specific receptor subtype.,Antagonist
15877932,The receptor(s) are: muscarinic and nicotinic acetylcholine. The subtype(s) are not specified. The binding mode(s) are: antagonist for both muscarinic and nicotinic receptors (mecamylamine and scopolamine). Therefore the mechanism of action is: muscarinic and nicotinic acetylcholine receptor antagonists.,Antagonist
16939663,"There is no specific drug being evaluated in this article, as it is a study on the effectiveness and factors predicting favorable outcome of risperidone long-acting injection (RLAI), an atypical antipsychotic.",Antagonist
10633487,This article does not discuss the evaluation of drugs with specific mechanisms of action or receptor subtypes. It focuses on the investigation of instrumental techniques to detect motor changes in patients with low levels of antipsychotic dopamine D2 blockade.,Antagonist
15719226,"The drugs being evaluated are amisulpride and risperidone, which are both atypical antipsychotics. The target of the chemical reaction is D2/D3 dopamine receptors in the striatum. The receptor subtype(s) are D2/D3 dopamine receptors. The binding mode is not mentioned in the abstract.",Antagonist
10481838,The mechanism of action of haloperidol is as a dopamine antagonist. There are no mentioned receptor subtypes in the article.,Antagonist
16262589,The mechanism of action is: opioid receptor antagonist. The target(s) and subtype(s) are: not specified. The drug being evaluated is naltrexone.,Antagonist
1375801,The article did not provide information about the mechanism of action(s) or receptor subtype(s) for either risperidone or haloperidol.,Antagonist
15863796,"The article does not provide information about the mechanism of action or receptor subtype of the drugs used in the study. The drugs evaluated were olanzapine, haloperidol, and placebo.",Antagonist
11407439,"The drug being evaluated is bromperidol, a selective dopamine antagonist. The target of the chemical reaction is the dopamine receptors, specifically the dopamine D2 receptor subtype.",Antagonist
16123775,The drugs being evaluated are olanzapine and haloperidol. The target receptors are dopamine D2/D3 and 5-HT2A. The binding mode is antagonist for both drugs.,Antagonist
16887890,"The article discusses two medications, disulfiram and naltrexone, for the treatment of alcohol dependence in patients with comorbid mental illness, but does not provide information on their mechanism of action or receptor subtypes targeted.",Antagonist
14658949,"The mechanism of action of risperidone is not specified in the article, but it is known to be an atypical antipsychotic that affects dopamine and serotonin receptors. No specific receptor subtype(s) are mentioned in relation to tardive dyskinesia treatment.",Antagonist
14627846,There is no specific drug being evaluated in this article. The article is discussing the use of a PET tracer called 11C-raclopride to measure D2 dopamine receptor binding in the striatum and thalamus.,Antagonist
15677610,"The drug being evaluated is ketamine, which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The mechanism of action is the blockade of NMDA receptors, which leads to increased glutamate activity in the anterior cingulate, as proposed by the NMDAR hypofunction model of schizophrenia.",Antagonist
7534423,"The drug being evaluated in the article is raclopride, which is a dopamine antagonist of the substituted benzamide class. Its mechanism of action is to block dopamine receptors, specifically D2 receptors. There is no mention of receptor subtypes in the article.",Antagonist
11147928,The article does not mention any drugs being evaluated with receptors or their mechanism of action. It solely discusses the effect of paroxetine and sertraline on the plasma concentrations of clozapine and its metabolites in patients with schizophrenia or schizoaffective disorder.,Antagonist
17591658,"The drugs being evaluated are: S-ketamine and N,N-dimethyltryptamine (DMT). The mechanism of action and receptor subtype(s) are not mentioned in the abstract.",Antagonist
17460616,"The drug being evaluated in this study is haloperidol, which is a dopamine D2-like receptor antagonist. Therefore, the mechanism of action of haloperidol is as a dopamine antagonist, specifically at the D2 receptor subtype.",Antagonist
16309810,The article does not mention any specific drug or receptor subtype being evaluated as it is a retrospective study comparing the efficacy of buprenorphine in different subgroups of dually diagnosed and non-dually diagnosed opioid-dependent patients.,Antagonist
16555163,"The article does not provide information on the mechanism of action or receptor subtype of amisulpride. However, it is described as a selective dopamine D2/D3 receptor antagonist with proven antipsychotic efficacy.",Antagonist
15358979,"The drugs being evaluated in this article are olanzapine and clozapine, both antipsychotic agents. The mechanism of action is to antagonize dopamine D2 receptors and serotonin 5-HT2 receptors. The receptor subtype is dopamine D2-like receptors.",Antagonist
19011428,"The drug being evaluated is ziprasidone, and its mechanism of action is as a D2/D3 receptor antagonist. The receptor subtype(s) are D2 and D3 receptors.",Antagonist
18179309,The mechanism of action for mirtazapine is presynaptic alpha2 antagonism and postsynaptic 5-HT2 and 5-HT3 antagonism. The drug is not being evaluated with a specific receptor subtype in this study.,Antagonist
11236069,The mechanism of action for pindolol is dual beta and 5-HT1A blocking effect. The target receptors are beta-adrenergic and serotonin receptors. There is no information on the specific subtypes of these receptors.,Antagonist
11001281,The mechanism of action of biperiden is blocking muscarinic acetylcholine receptors. There is no mention of any specific subtype(s) being evaluated.,Antagonist
11391124,The mechanism of action is: dopamine uptake inhibitor. The receptor subtype(s) are not mentioned in the abstract.,Antagonist
9376336,"The drugs being evaluated in this study are olanzapine and haloperidol, both of which are antipsychotic agents. The mechanism of action/target of the chemical reaction is the dopamine receptor. The subtype(s) of the dopamine receptor affected by these drugs is not specifically mentioned in the article.",Antagonist
17102980,There is no drug being evaluated in this study. The study is investigating the impact of polymorphisms in dopamine and serotonin receptor genes on the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.,Antagonist
9286184,"The article does not provide information on the specific mechanism of action or receptor subtype of olanzapine or haloperidol. However, both drugs are classified as antipsychotic agents and haloperidol is a dopamine 2 antagonist, while olanzapine has broad-based pharmacology encompassing serotonin, dopamine, muscarinic, and adrenergic receptor binding affinities.",Antagonist
12590356,"The article does not provide information about the specific mechanism of action, target of the chemical reaction, or receptor subtype(s) of risperidone and olanzapine.",Antagonist
14604455,The article does not provide information on the mechanism of action or receptor subtype(s) of the drugs being evaluated.,Antagonist
15537676,The mechanism of action for ketamine is as an antagonist for the N-methyl-D-aspartate (NMDA) receptor. The receptor subtype is the NMDA receptor.,Antagonist
12657913,"The drugs being evaluated are histamine H1-receptor antagonists: promethazine and homochlorcyclizine. They are both inhibitors of CYP2D6, an enzyme responsible for the metabolism of haloperidol and reduced haloperidol. Therefore, the mechanism of action is inhibiting CYP2D6-catalyzed metabolism of haloperidol and reduced haloperidol resulting in increased steady-state plasma concentrations. There are no receptor subtypes involved in this study.",Antagonist
12923824,"The drug being evaluated in this study is nizatidine, which is a histamine H2 antagonist. The mechanism of action is blocking the histamine H2 receptor, which reduces the production of acid in the stomach. There is no mention of any specific receptor subtype being targeted.",Antagonist
7691017,"The article does not provide information on the mechanism of action or receptor subtypes for either risperidone or haloperidol, as it primarily focuses on the comparative efficacy and safety of the two drugs in treating chronic schizophrenic patients.",Antagonist
15983801,The article does not mention the mechanism of action or receptor subtype targeted by ketamine.,Antagonist
12236625,"The drug(s) being evaluated are risperidone and olanzapine, both of which are atypical antipsychotic drugs. The mechanism of action is: dopamine D2 receptor blockade. The receptor subtype(s) is/are: dopamine D2 receptor.",Antagonist
9090332,"The article does not mention any specific mechanism of action or receptor subtype targeted by the drugs being evaluated (olanzapine, placebo, and haloperidol).",Antagonist
8097114,"The drug used in the study is raclopride, which is a D2-dopamine receptor antagonist. The receptor subtype is D2-dopamine receptor. The mechanism of action is selective occupancy of the D2-dopamine receptors.",Antagonist
11819152,"The article does not specify the mechanism of action or receptor subtype for the anticholinergic drugs that were withdrawn. However, anticholinergic drugs generally block the action of the neurotransmitter acetylcholine at muscarinic receptors in the brain and body.",Antagonist
1981070,The mechanism of action is calcium channel blocking. There is no specific receptor subtype mentioned in the article.,Antagonist
12766931,"The drug being evaluated is nefazodone, which blocks postsynaptic 5HT2A receptors and weakly inhibits serotonin reuptake. The mechanism of action is through antagonism at 5-HT2 receptors, which may reduce neuroleptic-induced extrapyramidal side effects. No specific receptor subtypes are mentioned.",Antagonist
12824745,The article does not provide information on the mechanism of action or receptor subtype(s) of the drugs being evaluated (haloperidol and atypical neuroleptics).,Antagonist
15551193,"The drug in question is zotepine, which is described as a D (2)5HT (2A) antagonist. This suggests that it acts by blocking both dopamine D2 and serotonin 5HT2A receptors. It is not specified whether there are other receptor subtypes involved in its mechanism of action.",Antagonist
7683702,"The drugs being evaluated are risperidone and haloperidol, both of which are antipsychotic agents. The article does not specify their target receptors or mechanism of action.",Antagonist
15504428,"The article does not provide information on the mechanism of action or receptor subtype targeted by haloperidol and risperidone. Haloperidol is a conventional dopamine antagonist neuroleptic, while risperidone is an atypical neuroleptic.",Antagonist
11697576,"The drugs being evaluated are antipsychotic agents: clozapine, olanzapine, risperidone, sulpiride, and haloperidol. The mechanism of action for all of these drugs is that they are dopamine antagonists. The receptor subtype targeted is the D2 dopamine receptor.",Antagonist
6857251,"The drug being evaluated is pimozide, which is a dopamine receptor blocker. There is no information provided about specific receptor subtype(s) being targeted.",Antagonist
8105790,The mechanism of action is opioid antagonist. The drug being evaluated is nalmefene which is a opioid antagonist. The target of the chemical reaction is the opioid system.,Antagonist
2567742,"The mechanism of action and receptor subtype(s) are not clearly stated in the article. However, it is mentioned that proglumide is a cholecystokinin (CCK) antagonist and that the study was investigating the interaction between CCK and dopamine in the brain in the treatment of refractory schizophrenia.",Antagonist
10870876,The article does not provide information about the mechanism of action or receptor subtype(s) of the drug risperidone.,Antagonist
29592,"The article does not provide information on the mechanism of action or receptor subtype of the drugs being evaluated (butaperazine and loxapine). However, they are both dopamine antagonists, which is mentioned in the abstract.",Antagonist
8726544,"The drug being evaluated is naloxone, which is an opioid antagonist. The mechanism of action is blocking the effects of endogenous opioids in the brain. There is no specific receptor subtype mentioned in the article.",Antagonist
2688781,"The mechanism of action of the drugs is not explicitly stated in the article. However, pimozide is described as a dopamine antagonist neuroleptic, while lithium is a mood stabilizer.",Antagonist
11223117,There are no drugs being evaluated in this study. The study is investigating the relationship between a genetic polymorphism in the dopamine D2 receptor and extrapyramidal adverse effects of antipsychotic drugs with DRD2 antagonistic properties in schizophrenic patients.,Antagonist
1103206,"The article does not mention any specific drugs or receptor subtypes that were evaluated. The study compared the therapeutic effects of two prototypic neuroleptics, haloperidol and chlorpromazine, and investigated the nontherapeutic effects of trihexyphenidyl on the treatment process. Trihexyphenidyl is an antiparkinson agent with anticholinergic properties. The article suggests that the degree of inherent anticholinergic activity may be an important determinant of potency differences among neuroleptics.",Antagonist
9372530,"The drugs being evaluated in this study are antipsychotic substances quetiapine, clozapine, and haloperidol. The mechanism of action is blocking dopamine-2 (D2) receptors, which are targeted by all three drugs. Quetiapine and clozapine are considered to be atypical antipsychotics due to their relatively weak striatal D2 receptor blocking property, which results in a lower propensity to induce extrapyramidal motor side-effects (EPS) compared to haloperidol. The study used 123I-iodobenzamide (IBZM) as a tracer substance to measure D2 receptor occupancy using single photon emission computed tomography (SPECT).",Antagonist
7536945,The mechanism of action is dopamine D2 receptor blockade. The receptor subtype is D2. The drugs being evaluated are risperidone and remoxipride.,Antagonist
10468316,The mechanism of action is: serotonin (5-HT)2 and D2 receptor blockade. The receptor subtype(s) are: 5-HT2 and D2 receptors. The drug being evaluated is nefazodone.,Antagonist
6407052,"The article does not explicitly state the mechanism of action or receptor subtype being targeted by the drugs being evaluated (fusaric acid, L-dopa, d-amphetamine, and placebo).",Antagonist
9623031,The mechanism of action of risperidone is a serotonin-dopamine antagonist antipsychotic in a class of benzisoxazole derivative. There is no specific information provided about the receptor subtype(s) targeted by risperidone.,Antagonist
18575849,The article doesn't provide information about the mechanism of action or receptor subtype of the drugs being evaluated (risperidone and haloperidol). They are both antipsychotic agents.,Antagonist
18515465,The mechanism of action of the drug topiramate is as a glutamate antagonist. There is no mention of a specific receptor subtype targeted by the drug in the article.,Antagonist
22464973,"The drug being evaluated is JNJ-37822681, which is a highly selective dopamine D₂ receptor antagonist with a rapid dissociation rate from the dopamine D₂ receptor. Therefore, the mechanism of action is dopamine D₂ receptor antagonism.",Antagonist
10898926,"The article is not evaluating drug mechanisms of action or receptor subtypes, but rather investigating the relationship between a specific genetic polymorphism (Taq1 A polymorphism of dopamine D(2) receptor gene) and extrapyramidal adverse effects of two antipsychotic medications (bromperidol and nemonapride) in schizophrenia patients.",Antagonist
23805859,The mechanism of action for the drug naltrexone is as an opioid receptor antagonist. The receptor subtype is the opioid receptor.,Antagonist
15076014,"The mechanism of action of mirtazapine is related to its alpha2 antagonism and postsynaptic 5-HT2 and 5-HT3 antagonism, which enhance noradrenergic and serotonergic transmission. The drug is not evaluated with a specific receptor subtype.",Antagonist
8584610,"The drug being evaluated is SCH 39166, which is a selective D1-dopamine receptor antagonist. Therefore, the mechanism of action is D1-dopamine receptor antagonism. The receptor subtype is D1-dopamine receptor.",Antagonist
11981237,The mechanism of action is: N-Methyl-D-Aspartate receptor antagonist. The receptor subtype(s) evaluated is: N-Methyl-D-Aspartate receptor. The drug being evaluated is: ketamine.,Antagonist
23067311,"The drug being evaluated is GSK1144814, which is a selective dual antagonist of NK1 and NK3 receptors. Therefore, the mechanism of action is NK1/NK3 receptor antagonism.",Antagonist
16220331,The mechanism of action is: N-methyl-D-aspartate (NMDA) receptor antagonist. The receptor subtype(s) is/are: NMDA glutamate receptor.,Antagonist
20299191,"The mechanisms of action of both drugs are as follows:
- Glycopyrrolate: muscarinic receptor antagonist
- Biperiden: muscarinic receptor antagonist

The article does not specify which muscarinic receptor subtype(s) the drugs are being evaluated with.",Antagonist
14764214,"The drugs being evaluated in this article are antipsychotics, specifically risperidone, and their mechanism of action is dopamine receptor antagonism. The receptor subtype being targeted is the dopamine D2 receptor.",Antagonist
16228196,"The drug evaluated in the study is ketamine, which is an NMDA antagonist. The receptor subtype(s) are NMDA receptors. The mechanism of action is blocking the receptor and inhibiting the action of glutamate, which is a neurotransmitter involved in cognitive function.",Antagonist
28086010,The article does not specify any drugs being evaluated with specific mechanisms of action or receptor subtypes. It instead investigates the threshold of dopamine D2/3 receptor occupancy for hyperprolactinemia in older patients with schizophrenia.,Antagonist
9885791,"The drug being evaluated is ketamine, which is an antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor. The receptor subtype is the NMDA receptor. The mechanism of action is NMDA receptor antagonist.",Antagonist
9778665,The drug is ketamine and the receptor subtype is N-methyl-D-aspartate (NMDA) receptor. The mechanism of action is NMDA receptor antagonism.,Antagonist
18755817,The drug talnetant is evaluated as an NK-3 antagonist. The receptor subtype is the neurokinin-3 receptor.,Antagonist
28120486,"The mechanism of action is inhibition of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE), specifically PDE9A. There are no receptor subtypes mentioned in the article. The drug being evaluated is BI 409306, an oral PDE9A inhibitor.",Antagonist
22113087,"The drug being evaluated is a glycine transporter-1 (GlyT1) inhibitor, and its mechanism of action is to enhance glutamate function by inhibiting the reuptake of glycine, which stimulates the glycine site of the NMDA receptor. Therefore, the receptor subtype being targeted is the NMDA receptor. The specific chemical reaction and binding mode of the drug are not specified in the article.",Antagonist
35502897,"The drugs being evaluated are: biperiden (muscarinic acetylcholine receptor antagonist) and amisulpride (dopamine D2/D3 receptor antagonist). The mechanism of action for biperiden is to block the muscarinic acetylcholine receptors, while the mechanism of action for amisulpride is to block the dopamine D2/D3 receptors. The receptor subtype(s) for biperiden are muscarinic acetylcholine receptors, and for amisulpride, D2 and D3 dopamine receptors. Galantamine and levodopa were also used but did not appear to have significant effects on MMN.",Antagonist
23118022,"The drugs being evaluated in this study are aripiprazole, haloperidol, and reserpine, all of which are antidopaminergic agents. The mechanism of action is the modulation of dopaminergic systems. The receptor subtype(s) are not specified.",Antagonist
17591660,"The drug being evaluated is ketamine, which is an N-methyl-D-aspartate (NMDA) antagonist. The mechanism of action is the inhibition of the NMDA receptor.",Antagonist
3129746,"The drug evaluated in the study is ritanserin, which is a specific serotonin-S2-antagonist. The mechanism of action is inhibiting serotonin receptor subtype 2, and there is no mention of any other receptor subtype being evaluated in this study.",Antagonist
14603267,The mechanism of action is: NMDA receptor antagonist. The receptor subtype(s) are: NMDA receptors. The drug being evaluated is ketamine.,Antagonist
21223356,"The drugs being evaluated are risperidone and SB-742457. 
Risperidone is a D(2)/5-HT(2A) antagonist with low affinity for 5-HT(6) receptors. 
SB-742457 is a potent 5-HT(6) antagonist.
The mechanism of action for risperidone is: dopamine and 5-HT receptor antagonist. The mechanism of action for SB-742457 is: 5-HT(6) antagonist. Receptor subtypes are: D(2)/5-HT(2A) for risperidone and 5-HT(6) for SB-742457.",Antagonist
19512973,The mechanism of action is: N-methyl-D-aspartate receptor antagonist. The receptor subtype(s) are: NMDA receptors. The drug being evaluated is ketamine.,Antagonist
9682999,"The drugs being evaluated are amisulpride and flupentixol. Amisulpride is a selective D2-like dopamine antagonist, while flupentixol blocks D2-like, D1-like and 5-HT2 receptors. Therefore, amisulpride targets D2-like receptors and flupentixol targets D2-like, D1-like, and 5-HT2 receptors.",Antagonist
22980315,The article does not provide information on the mechanism of action or receptor subtype(s) of bitopertin (RG1678).,Antagonist
27342447,The mechanism of action is NMDA receptor antagonist. The receptor subtype is NMDA. The drug being evaluated is ketamine.,Antagonist
10693157,"The drug is ketamine, which is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a subtype of the glutamate receptor.",Antagonist
31773211,The mechanism of action of TAK-063 is as a phosphodiesterase 10A inhibitor. There is no mention of receptor subtypes being evaluated in this study.,Antagonist
17452287,The mechanism of action is: NMDA receptor antagonist. The subtype(s) are: N/A. The drug being evaluated is: memantine.,Antagonist
10943910,The mechanism of action is: non-competitive NMDA antagonist. The receptor subtype(s) are: NMDA receptors.,Antagonist
20838215,"The mechanism of action of Trazodone is not clearly outlined in the article, but it is described as an antidepressant agent with prominent serotonergic antagonistic properties. It is suggested that its property of serotonin 2A postsynaptic receptor antagonism may be its principal mechanism for the improvement of NIA. There is no mention of receptor subtypes.",Antagonist
9683005,"The drug being evaluated is ketamine, which is an NMDA receptor antagonist. There is no specific subtype mentioned in the article.",Antagonist
28350401,"The article is not describing the evaluation of drugs, but rather studying the effects of systemic inflammation on stimulant-induced striatal dopamine elevation. No specific drugs or receptors are mentioned in the abstract.",Antagonist
30003027,The mechanism of action is: NMDAR antagonist. The receptor subtype(s) are: NMDA receptors. The drug being evaluated is S-Ketamine.,Antagonist
15936063,"The mechanism of action is: muscarinic and nicotinic receptor modulation. The receptor subtype(s) are: muscarinic and nicotinic receptors. The binding mode(s) are: antagonism (mecamylamine, scopolamine) and simultaneous antagonism of both receptor types (mecamylamine+scopolamine).",Antagonist
9433341,There is no drug being evaluated in this article.,Antagonist
22813429,"The article does not provide information on the mechanism of action, target of the chemical reaction, or receptor subtype of the drug being evaluated (ketamine). The article instead focuses on the effects of ketamine on sense of agency and intentional binding in relation to schizophrenia.",Antagonist
20947068,The mechanism of action is: noncompetitive N-methyl-D-aspartate antagonist. The receptor subtype(s) are: N-methyl-D-aspartate receptors. The drug being evaluated is ketamine.,Antagonist
11351929,"The mechanism of action is anticholinergic. The target of the chemical reaction is not specified in the article, but since the drug is referred to as an anticholinergic, it is likely that it acts on muscarinic acetylcholine receptors. The subtype(s) are not specified in the article.",Antagonist
19890262,The mechanism of action is NMDA antagonist (ketamine). The receptor subtype(s) are NMDA receptors.,Antagonist
21723949,"The mechanism of action of the drug is: glutamatergic system modulation. The drug being evaluated is ketamine, which is an NMDA receptor antagonist.",Antagonist
2899186,The article does not provide information about the mechanism of action or receptor subtype of the drugs being evaluated (pimozide and lithium).,Antagonist
12680739,The mechanism of action is: NMDA neurotransmitter system antagonism. The subtype(s) are: NMDA receptors. The drug being evaluated is (S)-ketamine.,Antagonist
7530376,"The receptor(s) are: 5-HT2 and D2 dopamine. The subtype(s) are: N/A. The binding mode is: antagonist. Therefore the mechanism of action is: combined 5-HT2 and D2 dopamine receptor blockade. Specifically, the drug being evaluated is risperidone, which has a high affinity for both 5-HT2 and D2 dopamine receptors.",Antagonist
8725991,The mechanism of action for risperidone is as an antipsychotic agent and dopamine antagonist. The receptor subtypes targeted were not specified in the article.,Antagonist
11763011,"The mechanism of action for cyproheptadine is as an antiserotonergic agent, and propranolol acts as an adrenergic beta-antagonist. The receptor subtype(s) are not specified in the article.",Antagonist
7545159,The mechanism of action of risperidone is as an atypical antipsychotic agent with potent dopaminergic and serotonergic antagonist activity. There are no specific receptor subtypes mentioned for this drug in the article.,Antagonist
19713555,The mechanism of action is as a dopamine D(2)- and serotonergic 5-HT(2A)-receptor antagonist. The receptor subtype(s) targeted are dopamine D(2) and serotonergic 5-HT(2A).,Antagonist
18227836,"The article does not mention any specific drugs being evaluated. Instead, it investigates the effects of disrupting the oxytocin gene in mice and how it affects their susceptibility to the psychosis-related effects of amphetamine, apomorphine, and phencyclidine.",Antagonist
20589598,"The article does not provide information on the mechanism of action or receptor subtype(s) for clozapine, ziprasidone, or risperidone.",Antagonist
11459878,"There are no drugs being evaluated in this article. Instead, the method used is repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in humans to induce dopamine release in the caudate nucleus.",Antagonist
36305696,There is no information in this article about specific drugs or their mechanisms of action and receptor subtypes.,Antagonist
1701262,The mechanism of action of the drug risperidone is as a combined serotonin-dopamine antagonist. The article does not specify any receptor subtype(s) that the drug is being evaluated with.,Antagonist
17239041,The mechanism of action for perospirone is as an atypical antipsychotic with potent serotonin 5-HT2 and dopamine D2 antagonist activity. There is no information provided about specific receptor subtypes being targeted.,Antagonist
32876732,"The mechanism of action of the drug is to act as a muscarinic antagonist, with atropine being the drug being evaluated. The receptor subtype(s) are the muscarinic receptors, specifically the M1 and M3 subtypes, which are responsible for salivation.",Antagonist
15683753,"There are no drugs being evaluated in this article, only a genetic polymorphism in the adrenergic alpha2C receptor (ADRA2C) and its potential association with clinical response and cognitive improvement to antipsychotic treatment.",Antagonist
7570351,There are no drugs being evaluated in this article. The study uses positron emission tomography (PET) to measure the variability of D2-dopamine receptor binding parameters in healthy subjects.,Antagonist
20490472,The article does not provide information about the mechanism of action or receptor subtypes for blonanserin.,Antagonist
34887529,"The article does not specify the mechanism of action or receptor subtype for either olanzapine or samidorphan. However, the study investigates the metabolic effects of these drugs on insulin and glucose metabolism in healthy volunteers.",Antagonist
10831017,"The article does not provide information on the mechanism of action or receptor subtype(s) of olanzapine and clozapine. However, it does mention that they have anticholinergic effects. The study specifically evaluated the anticholinergic effects of these medications in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder.",Antagonist
21603893,The mechanism of action of the drug ketamine is as an excitatory amino acid antagonist. The target of the chemical reaction is the NMDA receptor.,Antagonist
8681493,"The mechanism of action(s) and receptor subtype(s) listed in the article are: 
- D2 and D3 receptors (antipsychotic effects)
- 5-HT1a receptor (may contribute to antipsychotic and anxiolytic effects)
- alpha 1 receptor (may contribute to hypotensive effect)

Therefore, the mechanism of action is: antipsychotic (via D2 and D3 receptors), anxiolytic (via 5-HT1a receptor), and hypotensive (via alpha 1 receptor).",Antagonist
7965150,"The article does not discuss any drugs being evaluated, rather it discusses the use of a radiolabeled benzamide ([123I]-(S)-IBZM) as a tracer for detecting melanoma metastases.",Antagonist
17541696,"The drug being evaluated is S-ketamine, and the receptor subtype being studied is the 5-HT(2A) receptor. However, the article is not focused on the mechanism of action of the drug or receptor subtype.",Antagonist
17912501,"The drug is sulpiride, which is a dopamine antagonist. The receptor subtype being evaluated is the dopamine D2 receptor.",Antagonist
8666562,"The mechanism of action for risperidone is as a 5-HT2 and D2 antagonist, which means it targets both the serotonin and dopamine receptors. The specific receptor subtypes are not mentioned in this article.",Antagonist
9498724,The mechanism of action of ketamine is N-methyl-D-aspartate (NMDA) receptor antagonist. The receptor subtype(s) is NMDA. The mechanism of action of lorazepam is gamma-aminobutyric acid (GABA) receptor agonist. The receptor subtype(s) is GABA-A.,Antagonist
30006361,"The drug being evaluated is propranolol, which is a beta-blocker that modulates noradrenaline function. It does not act on a specific receptor subtype but rather blocks the activity of beta-adrenergic receptors. Amisulpride, another drug mentioned in the article, is a dopamine antagonist.",Antagonist
30390684,"The drug mentioned in the article is GSK561679, which is a CRF1 receptor antagonist. There is no information provided about the receptor subtype(s). The drug does not have a specific binding mode mentioned in the article.",Antagonist
30624551,"The drugs being evaluated are naltrexone and ketamine. The mechanism of action for naltrexone is as an opioid receptor antagonist, while ketamine is an NMDA receptor antagonist. There is no mention of specific receptor subtypes being targeted.",Antagonist
22626890,"The article does not provide information on the mechanism of action or receptor subtypes of the drugs used in the study. The drugs evaluated were buprenorphine/naloxone (Bup/Nal), a combination medication used for medication-assisted treatment for opioid dependence.",Antagonist
